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Abstract 
          Mechanistic target of rapamycin (mTOR) plays an essential role in sensing a 
myriad of environmental cues including nutrients and growth factor stimulation to 
regulate cell growth and proliferation. mTOR independently associates with different 
proteins to form two distinct complexes, mTORC1 and mTORC2. The previous 
antiangiogenesis study of antifungal drug itraconazole in endothelial cells showed that 
inducing lysosomal lipid accumulation inhibits mTORC1 signaling. On the other hand, 
lysosomal lipid accumulation blocks lysosomal calcium release. However, the 
mechanism by which lysosomal calcium regulates mTORC1 has remained undefined. In 
this work, we used pharmacological and genetic methods to illustrate that proper 
lysosomal calcium release through the calcium channel TRPML1 (transient receptor 
potential cation channel, mucolipin 1) is required for mTORC1 activation by inducing 
association of calmodulin (CaM) with mTOR. Moreover, we showed CaM is capable of 
stimulating the kinase activity of mTORC1 in a calcium-dependent manner in vitro.  
          Bearing the strategy of inhibiting mTOR by inducing lysosomal cholesterol 
accumulation in endothelial cells, we sought to identify novel mTOR inhibitors by drug 
repurposing that potentially can be used in anti-angiogenesis and anti-cancer treatment. 
First, we further characterized the divergence of antiangiogenesis activity and 
hepatotoxicity of different stereoisomers of itraconazole by assessing in vitro 
antiangiogenic activity of itraconazole and each stereoisomer using human umbilical vein 
endothelial cells (HUVEC), as well as determining their hepatotoxicity using primary 
human hepatocytes in vitro and a mouse model in vivo. Of the four stereoisomers 
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contained in commercial itraconazole, we found that IT-C showed more potent 
antiangiogenic/antitumor activity with lower hepatotoxicity compared with itraconazole 
and other stereoisomers. Therefore, these results suggest that IT-C may be superior to the 
racemic mixture of itraconazole as an anticancer drug candidate due to its lower 
hepatotoxicity and improved antiangiogenic activity.  In addition to itraconazole, we also 
identified that selective estrogen receptor modulators (SERM), such as tamoxifen, inhibit 
angiogenesis and produce anti-breast cancer effect through blockade of cholesterol 
trafficking as well as inhibiting mTOR rather than estrogen receptor antagonism. 
Together, these results unraveled a previously unrecognized mechanism of angiogenesis 
inhibition by inducing lysosomal cholesterol accumulation, implicating cholesterol 
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Chapter 1: Introduction 
1.1 mTOR structure 
          Target of rapamycin (TOR), discovered from yeast mutants that resistant to the 
inhibitory effect of rapamycin (1, 2), is highly conserved in all eukaryotes including 
plants, worms, flies, and mammals. The mammalian TOR (mTOR, also known as 
mechanistic target of rapamycin) in humans is encoded by the MTOR gene (3, 4). mTOR 
independently associates with regulatory-associated protein of mammalian target of 
rapamycin (raptor) or rapamycin-insensitive companion of mTOR (rictor) to form two 
distinct complexes, mTORC1 and mTORC2, respectively. The two complexes share 
several common subunits, including the catalytic mTOR subunit, mammalian lethal with 
sec-13 protein 8 (mLST8), DEP domain containing mTOR-interacting protein 
(DEPTOR), and the Tti1/Tel2 complex (5). Among the remaining components, raptor 
and proline-rich Akt substrate 40 kDa (PRAS40) are specific to mTORC1, whereas 
rictor, mammalian stress-activated map kinase-interacting protein 1 (mSin1) protein 
observed with rictor 1 and 2 (protor1/2) are unique to mTORC2 (5).  
          Cryo-electron microscopy (cryo-EM) studies have shown that mTOR forms an 
obligate dimer with an overall rhomboid shape and a central cavity at a relatively low 
resolution (26 Å) (6). Subsequently, another study crystalized N-terminally truncated 
human mTOR and mLST8, which is a subunit shared by both mTORC1 and mTORC2, to 
disclose a more detailed structure of mTORC1 and its inhibition by rapamycin-FKBP12 
complex at a higher resolution (3.2 Å) (7). However, information of the arrangement of 
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the subunits within the complex was missing because mTOR was truncated and only 
mLST8 was presented, while raptor, the key subunit of mTORC1 was no included. A 
more resent study successfully obtained a high-resolution cryo-EM of mTOR complex 1 
including purified raptor and mLST8 from insect cells (8). The N-terminus of mTOR 
contains two α-helical solenoids. The larger section is a highly curved super-helix, while 
the smaller region adopts a relatively linear arrangement. Both sections are exposed to the 
environment, indicating a potential role in binding mTOR associated proteins. In addition, 
the larger and smaller regions of HEAT domains pack against one another, and the first 
HEAT repeat of the larger region interlocks with the adjacent mTOR FAT domain, 
through which the two mTOR subunits forms a dimer independent of Raptor (8), which 
makes mTORC1 a dimeric architecture and presented in a hollow lozenge shape, in 
which raptor and mLST8 form peripheral parts of the complex, respectively. Interestingly, 
mTOR kinase domain was not affected by the dimerization, indicating that the regulation 
of the kinase activity was mainly achieved by controlling the access of substrates.  
1.2 Regulation of mTOR signaling pathway 
          mTORC1 and mTORC2 differ in their sensitivity to rapamycin, upstream signals 
and downstream outputs (5). The mTORC1 complex integrates different extracellular and 
intracellular signal inputs, such as growth factors, amino acids, stress and energy status, 
to regulate cellular processes such as protein and lipid synthesis and autophagy, by 
phosphorylating and activating p70 S6 kinase (p70S6K) (9, 10) and eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1) (11, 12). In contrast, mTORC2 is 
involved in Akt phosphorylation and regulation of the cellular cytoskeleton (13). mTOR 
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directly binds to GTP-bound Rheb and is subsequently activated on the surface of the 
lysosome. Therefore, the activation of mTORC1 required the translocation of mTORC1 
onto lysosomes, where it encounters Rheb. This translocation is controlled by the Rag 
GTPase and the Ragulator complex in response to amino acids (14-16). Rag is a 
heterodimeric GTPase consisting of RagA or B in complex with RagC or D. Amino acids 
stimulate guanine nucleotide exchange in Rag. However, it is still controversial whether 
Rag delivers mTORC1 onto lysosomal surface or Rag is fixed on lysosomes, from where 
it recruits mTORC1 to lysosomal surface (16-19). However, amino acid-mediated mTOR 
translocation was no longer observed when Rag or Raptor expression was genetically 
knocked-down by RNA interference. The exact mechanism that how Rag translocate 
mTORC1 onto lysosomal is still remained determined.  
          Another requirement to activate mTORC1 is that Rheb (Ras-homolog enriched in 
brain) needs to be activated by binding to GTP in response to growth factors. Rheb is a 
farnesylated GTPase that is anchored to the surface of the lysosome (16, 20). Rheb 
directly binds (21) and activates mTOR in vitro and in vivo (22). Rheb knockdown 
abolishes S6K1 and 4EBP1 phosphorylation (23), whereas, overexpression of Rheb 
stimulates S6K1 and 4EBP1 phosphorylation (24, 25). Tuberous sclerosis complex 
(TSC), a GAP of Rheb localized on lysosomes, negatively regulates Rheb. It is also 
known that TSC is inhibited by activation of Akt in response to growth factors (26).  
          The regulation of mTORC1 by TSC-Rheb and amino acids-Rag are distinct. 
Amino acid starvation still induces dephosphorylation of S6K1, S6 and 4EBP1 in TSC2-
/- MEFs, suggesting TSC1/2 is not required for amino acid-mediated mTORC1 
regulation (27, 28). On the other hand, mTORC1 locked on lysosome still needs growth 
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factors and Rheb to be activated, although it is not dependent on amino acids and Rag 
(19). This indicates that activation of mTORC1 needs the availability of both amino acids 
and growth factor, to make sure mTORC1 is translocated onto lysosome, where it 
encounters and binds to Rheb, which is activated by growth factors. Rheb also interacts 
with Raptor and mLST8, however, the interaction was not affected by amino acids (29). 
In addition, the modulation of the interaction between mTOR and raptor was also 
evaluated. The recovery of Raptor co-immunoprecipitated with mTOR was negatively 
regulated by amino acids stimulation in HEK293T cells. However, mTOR kinase activity 
was inversely correlated with the strength of Raptor binding to mTOR in vitro (30). On 
the other hand, insulin stimulation did not affect mTOR-Raptor interaction although it 
increased S6K1 phosphorylation. 
          Two independent groups have reported that Vps34 plays a key role in mTORC1 
regulation by amino acids (31, 32). Vps34 (vacuolar protein sorting 34) belongs to Class 
III PI3K. It forms an active complex with another protein kinase Vps15 (33) and 
generates PtdIns(3)P (34-36). hVps34 activity was increased and decreased by amino 
acid stimulation and deprivation, respectively, in accordance with S6K phosphorylation 
(31). In addition, knockdown of hVps34 or overexpression of GFP-FYVE expression 
vector, which sequesters PtdIns(3)P therefore acts as a dominant negative to Vps34 
signaling, also inhibited S6K phosphorylation. The mechanism of how hVps34 regulates 
mTORC1 has not been clearly known. It has been reported that addition of amino acid 
evoked a rapid increase in intracellular Ca2+ concentration and S6K phosphorylation. 
Furthermore, hVps34 activity and PtdIns(3)P production were inhibited by pre-incubation 
with Ca2+ chelator, BAPTA-AM. These results suggest that Vps34 and mTOR is 
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downstream of Ca2+. In addition, they reported that calmodulin (CaM) interacts with 
mTOR in a Ca2+ and hVps34-dependent manner. These evidences suggested a model 
that amino acid increases Ca2+ influx, which increases the interaction of Ca2+/CaM with 
the hVps34-mTOR and consequently activates mTORC1. 
          In addition to the lysosome, the subunits of mTORC1 were also detected to in the 
nucleus (37-42), mitochondria (43-45), stress granules (46-48), cytoplasm (49-51) and at 
the plasma membrane (52) under different conditions. However, whether the subunits can 
form intact mTORC1 (53), and some of the mechanism and regulation are not fully 
understood.  
          Activated mTORC1 phosphorylates several downstream effectors, including S6K1 
and 4EBP1, via an interaction between raptor and a TOR signalling (TOS) motif in S6K 
and 4EBP (54-56). The serine/threonine kinase p70S6K1 is one of the most well-known 
downstream targets of mTORC1. The phosphorylation of S6K1 at Thr389 by mTORC1 
is required for its activation. The phosphorylated S6K by activated mTORC1 
phosphorylates S6 (40S ribosomal protein S6), enhancing the translation of mRNA (57). 
4EBP1 is another well-characterize mTORC1 target. 4EBP1 inhibits the initiation of 
protein translation by binding and inactivating eIF4E (eukaryotic translation initiation 
factor 4E) (58). mTORC1 phosphorylates 4EBP1 to promote the dissociation of eIF4E 
from 4EBP1 (59). Free eIF4E can form the multisubunit eIF4F complex, enabling cap-
dependent protein translation, and inducing increased translation of mRNAs (57). 
Multiple studies suggest a negative feedback loop from the mTOR-S6K1 pathway to the 
upstream IRS pathway (60, 61).  
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          Although mTORC1 activity is prone to multiple positive and negative regulations 
driven by extracellular growth factors and stress stimuli, mTORC2 regulation 
mechanisms remain largely unknown. In mammalian cells, mTORC2 phosphorylates Akt 
upon growth factor stimulation such as insulin, indicating that mTORC2 is regulated by 
the PI3K pathway (62, 63). However, the mechanism by which insulin or other growth 
factors activate mTORC2 is unclear. A recent study indicated that TSC1/TSC2 complex 
may play a key role in the regulation of mTORC2 by growth factor. In contrast to the 
negative regulation of mTORC1, TSC1/TSC2 complex positively regulate mTORC2 in a 
GAP-independent manner (64). The GTPase Rheb, which is a downstream of 
TSC1/TSC2 and activates mTORC1, does not appear to regulate mTORC2. 
1.3 mTOR in human cancer 
          Since mTOR plays the key role in cell growth and metabolism, it is not surprised 
that an abnormal mTOR pathway activity may exist in pathological states, including 
cancer. In a number of in vitro cell-lines and in vivo mice xenograft models, abnormal 
mTOR pathway activation through oncogene stimulation or loss of tumour suppressors 
contributes to tumour growth, angiogenesis and metastasis (57). Mutations in mTOR 
gene that confer constitutive activation of mTOR signaling under nutrient starvation 
conditions have been identified in a few human cancers (65). PI3K/AKT, the upstream 
signaling of mTORC1, is deregulated through a variety of mechanisms, including 
overexpression or activation of growth factor receptors, for examples, human epidermal 
growth factor receptor 2 (HER-2) and insulin-like growth factor receptor (IGFR), 
mutations in PI3K and mutations/amplifications of AKT (66-68). PTEN, the negative 
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regulator of PI3K signalling, was also reported to be decreased or lost its expression in 
many cancers (69, 70). mTOR downstream effectors S6K1, 4EBP1 and eIF4E are 
implicated in protein translation, and their overexpression has been linked to poor cancer 
prognosis (71-74).  
          Thus, the activation of mTOR has been reported to be lost control in many cancer 
types. Deregulation of multiple elements of the mTOR pathway has been discovered in 
cancer, such as breast, ovarian, renal, colon and head and neck cancers. Taken together, 
these data emphasizes the importance of mTOR signalling in cancer and reinforce the 
importance of considering mTOR targeting in cancer therapy. 
1.4 Strategy that small molecules inhibit mTOR 
          mTOR inhibitors can be classified into two groups: rapamycin and rapamycin 
analogues that allosterically inhibit mTORC1 and the small molecules that inhibit mTOR 
kinase activity.  
          Originally, rapamycin (rapamune, sirolimus) was used an immunosuppressive drug 
for prevention of renal allograft rejection (75). Subsequent studies demonstrated that 
rapamycin can also slow or arrest growth of different cancer cell lines (76-82). 
Furthermore, rapamycin also inhibits cell proliferation, survival and angiogenesis (83, 
84). Several rapamycin analogues have been developed with better pharmacokinetic c 
and solubility characteristics. Similarly to rapamycin, these analogues can form a 
complex with FKBP12 and further bind to mTOR and inhibit mTORC1 signaling 
pathway (85, 86). Currently, rapamycin and its analogues temsirolimus, everolimus and 
deforolimus are in clinical trials, and some of them showed encouraging results in a 
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subset of cancers (87-90). However, due to weak inhibition to phosphorylation of 4EBP1 
and failure inhibition of mTORC2, the antiproliferative effects of the analogues are 
variable in cancer cells in some tumour types. In addition, the specific inhibition of 
mTORC1 also raised an issue that the upstream receptor tyrosine kinase signaling and 
Akt might be up-regulated, leading to the drug resistance (91). Thus, the combination 
therapy that targets both mTOR and Akt may improve anti-cancer effect. 
          Another class of mTOR inhibitors binds to the ATP-binding site of mTOR and 
inhibit both mTORC1 and mTORC2 potently, and they showed better anti-cancer effects 
in preclinical studies compared with that of rapamycin analogues (92, 93). PP242 and 
Torin1, selective ATP-competitive mTOR inhibitors, have been reported to display more 
potent effects to inhibit protein synthesis, cell growth and proliferation (92, 93). These 
compounds need to be further evaluated in the cancer treatment to determined how they 
will be affected by up-regulated PI3K signaling. 
          Currently, several dual PI3K-mTOR inhibitors are under development (94-96). 
This class of compounds is undergoing clinical trials for cancer treatment, and was 
reported to prevent the activity of PI3K-mTOR axis biomarkers more effectively than 
rapamycin, by inhibiting both mTORC1 and mTORC2. 
          So far in most tumor types, mTOR inhibitors are predominantly stabilizing the 
disease rather than leading to tumor regression. Thus, combination therapies are usually 
necessary with the aim to induce a cytotoxic rather than a cytostatic response, and 
subsequent tumour regression. Multiple studies have evaluated mTOR inhibitors used in 
combination therapies with conventional chemotherapy agents, such as carboplatin, 
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cisplatin, vinorelbine, doxorubicin, paclitaxel, and camptothecin, and showed synergistic 
or additive effects (77, 97-99). 
          On the other hand, temsirolimus or everolimus has also been tested in combination 
with bevacizumab, sorafenib or sunitinib in clinical trials, given mTOR inhibitors 
downregulate HIF and VEGF.  
          Recently, another class of compounds that indirectly inhibit mTOR in endothelial 
cells has been reported (100), and itraconazole was one of them. This class of compounds 
induces lysosomal cholesterol accumulation, which mimics Niemann-Pick C phenotype, 
and subsequently inhibits mTOR activity in human umbilical vein endothelial cells 
(HUVEC) and produces anti-angiogenesis effects. Interestingly, the inhibition of mTOR 
by this class of compounds was reversed by increasing cytosolic calcium concentration. 
The essential role of cholesterol homeostasis in the activity of the mTOR pathway in 
endothelial cells suggests that the intracellular cholesterol trafficking pathway, including 
NPC1 and NPC2, may serve as a promising target for developing inhibitors of 
angiogenesis. However, the mechanism that how NPC phenotype leads to mTOR 
inhibition remains unknown. Several studies have reported that in NPC cells, the 
homeostasis of lysosomal calcium is disrupted (101), and lysosomal calcium release 
through TRPML1 is blocked (102). This raised a question that whether mTOR is 
regulated by Ca2+. 
          The goal of this thesis work has been to discover the mechanism of connection 
between NPC phenotype and mTOR inhibition, with the aim of understanding the novel 
regulator of mTOR signaling pathway, and therefore identify alternative strategy to 
inhibit mTOR activity. To accomplish this, I used pharmacological or genetic methods to 
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study the role of lysosomal calcium and calmodulin in mTORC1 activation in the cells, 
and evaluated the effect of Ca2+/CaM in regulating mTOR kinase activity in vitro as well 
(Chapter 2). In addition, following this strategy that inhibiting mTOR by inducing NPC 
phenotype, I studied different stereoisomers of itraconazole in mTOR inhibition in 
endothelial cells as well as hepatotoxicity (Chapter 3). Furthermore, this strategy also 
prompted us to identify a class of selective estrogen receptor modulators that inhibit 
mTOR signaling through blockade of cholesterol trafficking, and produces anti-
angiogenesis effect in breast cancers rather than estrogenreceptor antagonism (Chapter 
4). The relevance of these studies and future directions will be discussed in each chapter. 
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Chapter 2: Regulation of mTORC1 by  
Lysosomal Calcium and Calmodulin 
2.1 Abstract 
          Blockade of lysosomal calcium release due to lysosomal lipid accumulation has 
been shown to inhibit mTORC1 signaling. However, the mechanism by which lysosomal 
calcium regulates mTORC1 has remained undefined. Herein we report that proper 
lysosomal calcium release through the calcium channel TRPML1 is required for 
mTORC1 activation. TRPML1 depletion inhibits mTORC1 activity, while 
overexpression or pharmacologic activation of TRPML1 has the opposite effect. 
Lysosomal calcium activates mTORC1 by inducing association of calmodulin (CaM) 
with mTOR. Blocking the interaction between mTOR and CaM by antagonists of CaM 
significantly inhibits mTORC1 activity. Moreover, CaM is capable of stimulating the 
kinase activity of mTORC1 in a calcium-dependent manner in vitro. These results reveal 
that mTOR is a new type of CaM-dependent kinase, and TRPML1, lysosomal calcium 
and CaM play essential regulatory roles in the mTORC1 signaling pathway.  
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ABBREVIATIONS 
TRPML1, transient receptor potential cation channel, mucolipin subfamily, member 1; 
HUVEC, human umbilical vein endothelial cells; mTOR, mechanistic target of 
rapamycin; mTORC1, mTOR complex 1; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; S6K, ribosomal s6 kinase; 4EBP1, eukaryotic translation initiation factor 
4E-binding protein 1; CaM, calmodulin; MLC2, myosin light chain 2; CMDZ, 
calmidazolium; Rheb, Ras homolog enriched in brain. 
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2.2 Introduction 
          Mechanistic target of rapamycin (mTOR) plays an essential role in sensing a 
myriad of environmental cues including nutrients and growth factor stimulation to 
regulate cell growth and proliferation (1). mTOR independently associates with 
regulatory-associated protein of mammalian target of rapamycin (raptor) or rapamycin-
insensitive companion of mTOR (rictor) to form two distinct complexes, mTORC1 and 
mTORC2, respectively. The two complexes share several common subunits, including 
the catalytic mTOR subunit, mammalian lethal with sec-13 protein 8 (mLST8), DEP 
domain containing mTOR-interacting protein (DEPTOR), and the Tti1/Tel2 complex(2). 
Among the remaining components, raptor and proline-rich Akt substrate 40 kDa 
(PRAS40) are specific to mTORC1, whereas rictor, mammalian stress-activated map 
kinase-interacting protein 1 (mSin1) protein observed with rictor 1 and 2 (protor1/2) are 
unique to mTORC2(2). These two complexes differ in their sensitivity to rapamycin, 
upstream signals and downstream outputs(2). The mTORC1 complex integrates different 
extracellular and intracellular signal inputs, such as growth factors, amino acids, stress 
and energy status, to regulate cellular processes such as protein and lipid synthesis and 
autophagy, by phosphorylating and activating p70 S6 kinase (p70S6K)(3, 4) and 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)(5, 6). In contrast, 
mTORC2 is involved in Akt phosphorylation and regulation of the cellular 
cytoskeleton(7). Activation of mTORC1 by amino acids requires the translocation of 
mTORC1 from the cytosol to the surface of lysosomes, which is dependent on the Rag 
GTPase heterodimers Rag A/B and Rag C/D(8, 9).  
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 The second messenger calcium has been shown to play an important role in the 
regulation of mTOR signaling. Earlier hints that calcium might play a key role in mTOR 
signaling came from observations that calcium was required for the activation of 
p70S6K(10-12). But the underlying mechanism was attributed to upstream regulators 
such as PI3K or isoforms of PKC. More definitive roles of calcium and its signaling 
mediator calmodulin (CaM) in mTORC1 signaling were demonstrated in the context of 
amino acid activation of the pathway(13). It was shown that the phosphorylation of S6K1 
in response to amino acids or insulin was inhibited by the cell permeable calcium chelator 
BAPTA-AM while thapsigargin, which releases intracellular calcium, activated 
mTORC1 activity. Moreover, it was shown that the activation of mTORC1 by amino 
acids was inhibited by antagonists of CaM or its knockdown using siRNA, suggesting 
that CaM plays an essential role in mTORC1 signaling pathway. The underlying 
mechanism by which calcium and CaM regulate mTORC1 was attributed to the binding 
of calcium-activated CaM to the hVps34, leading to the activation of its kinase activity. 
While the sensitivity of mTORC1 to BAPTA-AM and CaM antagonists have been 
reproducibly seen, ensuing studies have cast some doubt on the notion that hVps34 is a 
key mediator of calcium and CaM in the regulation of mTORC1 in similar and other 
cellular systems(14, 15).  
     In a previous study, we found that the antifungal drug itraconazole inhibited 
mTOR due in part to its induction of lysosomal cholesterol and lipid accumulation, which 
mimics the phenotype of Niemann-Pick type C (NPC) disease(16). Moreover, other small 
molecules that are known to induce NPC phenotype also inhibited mTOR(16). 
Independently, it has also been reported that NPC cells showed significant defects in 
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lysosomal calcium homeostasis(17, 18). Cells that have mutant or deficient mucolipin 
transient receptor potential (TRP) channel 1 (TRPML1) display altered Ca2+ 
homoeostasis similar to that seen in NPC cells(19-21). Cells treated with chemical NPC 
inducers exhibited reduced TRPML1-mediated lysosomal Ca2+ release in response to a 
TRPML1 agonist, indicating dysfunction of this calcium channel. Furthermore, it has 
been shown that TRPML1 homolog in fly is required for TORC1 activation and fusion of 
amphisomes with lysosomes, and the inhibition of TORC1 can be rescued by feeding fly 
larvae with a high-protein diet, while TORC1 exerts reciprocal control on TRPML 
function, establishing the connection between TRPML and TORC1 signaling pathway in 
fly cells(22, 23). Whether TRPML1 regulates mTORC1 signaling pathway in mammalian 
cells remains unknown. Putting these findings together, we hypothesized that a defect in 
lysosomal calcium homeostasis in NPC cells might be responsible for the observed 
inhibition of the mTOR signaling pathway.  
 We validated our hypothesis by demonstrating that depletion of TRPML1 inhibits 
mTORC1 while overexpression or pharmacologic activation of TRPML1 activates 
mTORC1. We traced the likely site of regulation of mTORC1 pathway by calcium and 
CaM by determining the sensitivity of mTORC1 activity to BAPTA-AM and CaM 
antagonists in response to various upstream activators of the kinase complex and 
narrowed it to mTORC1 itself. We found that CaM directly binds to mTOR within its 
FAT domain, activating its kinase activity. Together, these findings shed significant new 
light on mTORC1 signaling pathway and offer a unifying mechanism that accounts for 
most, if not all, earlier observations implicating calcium and CaM in the regulation of 
mTORC1 by different upstream activators in distinct cellular context.  
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2.3 Materials and methods 
Cell lines and tissue culture 
          HEK293T (ATCC) and A549 (ATCC) cells were cultured in low glucose DMEM 
(Life Technology) supplemented with 10% FBS (Life Technology). Healthy human 
fibroblasts (Coriell Insititute, GM03440) and mucolipidosis IV human fibroblasts (Coriell 
Insititute, GM02048) were cultured in EMEM (ATCC) supplemented with 15% FBS. 
HUVEC (ATCC) were cultured in EGM media (Lonza). All cells were cultured at 37°C 
with the presence of 5% CO2. HEK293T cells were tested for mycoplasma contamination 
using a PCR mycoplasma test, and showed negative result. 
 
Leucine starvation and stimulation of the cells 
          Almost confluent cultures in 6-well plates were washed once with leucine-free low 
glucose DMEM (US Biological), incubated in leucine-free DMEM for 3 hr, and 
stimulated with 52 µg/ml leucine for 10 minutes. For those cells treated with 
calmidazolium (CMDZ, Cayman Chemical) or BAPTA-AM (Cayman Chemical), 
compounds were added 1 hr prior to cell harvesting. Cells were processed for 
biochemical assays as described below. 
 
Growth factor starvation and insulin stimulation of the cells 
          Almost confluent cultures in 6-well plates were washed once with FBS-free 
DMEM, incubated in FBS-free DMEM for 24 hrs, and stimulated with 600 nM insulin 
(Life Technology) for 10 minutes. For those cells treated with calmidazolium (CMDZ) or 
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BAPTA-AM, compounds were added 1 hr prior to cell harvesting. Cells were processed 
for biochemical assays as described below. 
 
Immunoblotting analysis 
          After indicated treatments, cells were washed once with ice-cold PBS and lysed in 
ice-cold RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM 
beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin). After brief sonication, the cell 
debris was removed by centrifugation at 13,000 rpm for 10 minutes in a microfuge, and 
the protein amount in the supernatant was quantified and mixed with a proper volume of 
5x SDS loading buffer. Proteins were then separated by SDS-PAGE and transferred to 
nitrocellulose membranes. After blocking at room temperature for 1 hour, membranes 
were immunoblotted with anti-p-S6K (T389) (1:1000, Cell Signaling Technology, Cat. 
9205), p-Akt (T308) (1:1000, Cell Signaling Technology, Cat. 9275), p-Akt (S473) 
(1:1000, Cell Signaling Technology, Cat. 9271), p-4EBP1 (S65) (1:1000, Cell Signaling 
Technology, Cat. 9451), p-mTOR (S2448) (1:1000, Cell Signaling Technology, Cat. 
2971), mTOR (1:1000, Cell Signaling Technology, Cat. 2983), Akt (1:1000, Cell 
Signaling Technology, Cat. 9272), raptor (1:1000, Cell Signaling Technology, Cat. 2280), 
PRAS40 (1:1000, Cell Signaling Technology, Cat. 2610), hVps34 (1:1000, Cell 
Signaling Technology, Cat. 3811), HA tag (1:1000, Santa Cruz Biotechnology, Cat. sc-
7392), myc tag (1:1000, Santa Cruz Biotechnology, Cat. sc-40), FLAG tag (1:5000, 
Sigma, Cat. F1804), GFP (1:1000, Santa Cruz Biotechnology, Cat. sc-9996), S6K 
(1:1000, Santa Cruz Biotechnology, Cat. sc8418), GAPDH (1:1000, Santa Cruz 
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Biotechnology, Cat. sc-20357) at 4°C overnight with the primary antibodies, followed by 
incubation with HRP-conjugated anti-mouse (1:10000, GE Healthcare, Cat. NXA931), 
anti-rabbit (1:10000, GE Healthcare, Cat. NA934V) or anti-goat IgG (1:10000, Santa 
Cruz Biotechnology, Cat. sc-2020) at room temperature for 1 hour. Antibody-protein 
complexes were detected using enhanced chemiluminescence (ECL) immunoblotting 
detection reagent. The band intensity was measured using ImageJ software (National 
Institute of Health, USA) 
 
CaM sepharose precipitation 
          Cells were washed once with ice-cold wash buffer (40 mM HEPES [pH 7.4], 150 
mM NaCl), and lysed in ice-cold lysis buffer (40 mM HEPES [pH 7.4], 150 mM NaCl, 
0.3% CHAPS or 1% NP-40 or 1% Triton-X100, phosphatase inhibitor cocktail (Sigma) 
and protease inhibitor cocktail (Roche)). The cell debris was removed by centrifugation 
at 13,000 rpm for 10 minutes in a microfuge. Five percent of the supernatant was 
reserved as “input”, and the rest of the supernatant was equally divided into two groups: 
one contained 1 mM CaCl2, and another one contained 5mM EGTA. The lysates were 
incubated with pre-washed CaM sepharose (GE Healthcare) at 4°C for 2 hrs with rotation. 
The beads were washed with CaCl2 (1 mM) or EGTA (5 mM) -containing CHAPS 
(0.3 %) buffer 3 times, and boiled at 95°C for 5 min. Elution of the protein from CaM 
sepharose was subjected to immunoblotting to analyze the recovery of indicated proteins 
or peptides. 
 
Immunoprecipitations and in vitro kinase assay 
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          Cells were washed once with ice-cold wash buffer (40 mM HEPES [pH 7.4], 150 
mM NaCl), and lysed in ice-cold CHAPS buffer (40 mM HEPES [pH 7.4], 150 mM 
NaCl, 2mM EDTA, 0.3% CHAPS, phosphatase inhibitor cocktail and protease inhibitor 
cocktail). The cell debris was removed by centrifugation at 13,000 rpm for 10 minutes in 
a microfuge. The soluble fractions of cell lysates were mixed with anti-raptor antibody (4 
µg/10cm dish, Life Technology, Cat. 42-4000), and the mixtures were incubated with 
rotation for 1.5 hours at 4°C. 80 µl of a 50% slurry of protein A/G plus-sepharose (Santa 
Cruz Biotechnology) was then added and the incubation continued for an additional 1 
hour. Immunoprecipitates were washed twice with ice-cold CHAPS buffer, and once with 
mTOR kinase buffer (25mM HEPES [pH 7.4], 50mM KCl, 10mM MgCl2). The kinase 
assays were performed as previously described (24). CaM (2 µM) or/and CaCl2 (0.2 mM) 
were added into the kinase reaction as indicated. CMDZ (8 µM) or Torin 1 (100 nM, 
Cayman Chemical) was incubated with the reaction mixtures 10 min prior to initiating 
the reaction by addition of 250 µM ATP (Sigma). The phosphorylation states of S6K or 
4EBP1 were detected by immunoblotting. 
 
Real-time qPCR 
          HEK293T, HUVEC and A549 cells were transduced with lentivirus carrying 
scramble shRNA or TRPML1 shRNA. Total RNA was collected using RNeasy Mini Kit 
(QIAGEN). cDNA was generated with SuperScript III First-Strand kit (Invitrogen), and 
real-time PCR was carried out using TaqMan Universal Master Mix II (Life 
Technologies). Real-time PCR primers and probes were from Thermo Fisher Scientific: 
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MCOLN1 FAM (Hs01100653_m1), TPCN2 FAM (Hs01552063_m1). Human GAPDH 
VIC (Hs02758991_g1) was used as an endogenous control. 
 
 
cDNA manipulations and mutagenesis 
          Myc-mTOR (Addgene plasmid # 1861), myc-mTOR (1-1482 aa) (Addgene 
plasmid # 21745), myc-mTOR (1271-2008 aa) (Addgene plasmid # 21746), myc-mTOR 
(1750-2549 aa) (Addgene plasmid # 21747), HA-GbL (Addgene plasmid # 1865), pRK5-
HA GST RagA 66L (Addgene plasmid # 19300), pRK5-HA GST RagC 75L (Addgene 
plasmid # 19305) and HA GST PreScission p70 S6K1 (Addgene plasmid # 15511) were 
gifts from David Sabatini. pcDNA3-FLAG-Rheb-N153T (Addgene plasmid # 19997) 
was a gift from Fuyuhiko Tamanoi. pcDNA-CaM was a gift from David Yue. TRPML1-
HA (Addgene plasmid # 18825) was a gift from Craig Montell. EGFP-Rab7A Q67L 
(Addgene plasmid # 28049) and EGFP-Rab7A T22N (Addgene plasmid # 28048) were 
gifts from Qing Zhong. 
          Myc-tagged truncated mTOR fragments were amplified by PCR and cloned into 
the EcoRI site of pRK5 or pEGFP vector. FLAG-tagged RhebN153T was amplified by 
PCR and cloned into the EcoRI site of pLVX-AcGFP-N1 vector. GST-tagged 4EBP1 
was amplified by PCR and cloned into a pDEST15-based vector. FLAG-tagged CaM was 
amplified by PCR and cloned into a pGEX6-based vector. TRPML1 was amplified by 
PCR and cloned into a pEGFP-based vector. All ligations were performed with Infusion 
Kit (Clontech Laboratories, Inc.) according to the manufacture’s instruction. After 
sequence verification, these plasmids were used, as described below, in transient cDNA 
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transfections, bacterial protein expression or to produce the lentiviruses needed to 
generate cell lines stably expressing the proteins. 
 
cDNA transfection-based experiments 
          For transfection experiments, HEK293T cells were seeded in 6-well plates or 6 cm 
culture dishes. After 24 hrs, cells were transfected with the pRK5-based cDNA 
expression plasmids indicated in the figures (500 ng of truncated mTOR fragments; 200 
ng HA-GST-tagged RagA 66L or RagC 75L, 1000 ng of EGFP-tagged TRPML1, and 
same amount of proper empty vectors) using Lipofectamine 2000 (Life Technology) 
according to the manufacturer’s instructions. 
 
Preparation of p70S6K1, HA-GST-TRD3, GST-4EBP1 and FLAG-CaM for Use in 
mTORC1 Kinase Assays 
         HA-GST-PreScission-p70 S6K1 was transfected into HEK293T cells as described 
above, and after 48 h the cells were treated with 20 µM LY294002 for 1 hr prior to cell 
harvesting and lysis. HA-GST-PreSciss-S6K1 was purified as described (25). The 
purified protein was stored at -80°C in 20% glycerol. 
          HA-GST-TRD3 expression plasmid (pRK5-based) was transfected into HEK293T 
cells. After 48 h, the cells were lysed with lysis buffer (PBS, pH 7.4, 1% triton X-100, 
protease inhibitor cocktails, phosphatase inhibitor cocktails) in ice and HA-GST-TRD3 
was tandemly purified using glutathione sepharose beads (GE healthcare) and anti-HA 
antibody-conjugated agarose beads (Thermo Fisher Scientific) according to the 
manufacturers’ instructions. 
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          GST-fused 4EBP1 protein was expressed and purified from BL21 (DE3) 
Escherichia coli. Bacteria were grown to an OD of 0.8 and induced for 16 hrs at 18°C 
with 0.5 mm IPTG (American Bioanalytical). Bacteria were pelleted, and lysed in ice-
cold PBS containing 1% Triton X-100, 1mg/mL lysozyme (Sigma-Aldrich) and protease 
inhibitor cocktail by sonication. Cell debris was cleared by centrifugation. The 
supernatant was mixed with pre-equilibrated glutathione sepharose 4B resin for 1 hour at 
4°C with rotation. After gentle centrifugation, GST-4EBP1 was eluted by 10 mM 
reduced glutathione, and the protein sample was desalted by PD-10 desalting columns 
and then eluted by the elution buffer (150mM NaCl, 40mM HEPES [pH 7.4]). The 
purified protein was stored at -80°C in 20% glycerol. 
          GST-FLAG-CaM protein was expressed and purified as GST-4EBP1. GST tag was 
removed by PreScission (GE Healthcare) according to the manufacturer’s instruction. 
The purified protein was stored at -80°C in 20% glycerol. 
 
Mammalian lentiviral shRNAs 
          TRC lentiviral shRNAs targeting hTRPML1, mTOR, hVps34 and raptor were 
obtained from Sigma. The TRC number for each shRNA is as follows: 
          Human mTOR shRNA #1: TRCN0000038677 
          Human mTOR shRNA #2: TRCN0000039785 
          Human raptor shRNA #1: TRCN0000039772 
          Human raptor shRNA #2: TRCN0000010415 
          Human TRPML1 shRNA #1: TRCN0000083297 
          Human TRPML1 shRNA #2: TRCN0000083296 
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          Human hVps34 shRNA #1: TRCN0000037794 
          Human hVps34 shRNA#2: TRCN0000037795 
          Human TPC2 shRNA #1: TRCN0000043919 
          Human TPC2 shRNA #2: TRCN0000043921 
          Human P2X4 shRNA #1: TRCN0000044960 
          Human P2X4 shRNA #2: TRCN0000044962 
 
Lentivirus production and cell transduction  
          HEK293T cells were seeded in 15-cm culture dishes. When 50-70% confluent, the 
cells were co-transfected with 9 µg lentiviral vector (empty, lentiviral vector containing 
sequences expressing indicated proteins, scramble shRNA or shRNA targeting indicated 
proteins) + 6 µg pspAX2 + 3 µg pMD2G using lipofectamine 2000 according to 
manufacturer’s instructions. After 24 hrs, 48 hrs and 72 hrs, the supernatants were 
harvested, respectively, and concentrated using PEG6000 as described before (26). The 
concentrated virus was stored at -80°C. 
          HEK293T cells were seeded in 10-cm culture dishes. When cells were 40% 
confluent, concentrated lentiviral solutions were added into the cell culture medium. 
After 48 hrs, cells were treated with antibiotics to select transduced cells. 
 
Immunostaining 
          Cells were fixed with 4% (wt/vol) paraformaldehyde in PBS for 20 min at room 
temperature (RT). After wash, cells were permeabilized by PBS/0.5% Triton X-100 and 
incubated at RT for 10 min. After blocking, cells were incubated with anti-mTOR 
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antibody (1:150, Cell Signaling Technology, Cat. 2983) at 4°C overnight, followed by 
incubating with Alexa Fluor® 568 (1:500, Life technologies, Cat. A11011) for 1 h at RT. 
Images were captured using a Zeiss LSM 700 confocal microscope. 
 
 
Data analysis  
        All graphs were created using GraphPad Prism software, and statistical analysis was 
performed with GraphPad Prism. Data are presented as the mean ± s.d. Two-tail t-test 
statistical comparisons were made using ANOVA. A P value < 0.05 was considered 
statistically significant. No statistical method was used to predetermine sample size. The 
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2.4 Results 
TRPML1 is required for the activation of mTORC1 
          To determine whether TRPML1 is required for mTORC1 signaling, HEK293T 
cells were transduced with lentiviral shRNA targeting human TRPML1 (Sh1 and Sh2) or 
a scrambled shRNA (Scr). Due to a lack of reliable hTRPML1 antibodies, the 
knockdown efficiency was assessed by RT-qPCR, as well as indirectly by the expression 
level of ectopically expressed EGFP-TRPML1. The activity of mTORC1, as judged by 
the phosphorylation of S6K, was significantly inhibited upon TRPML1 knockdown, 
while the phosphorylation of Akt (T308) was not affected (Figure 2.1 a).  
          To determine whether the mTOR inhibition caused by TRPML1 knockdown was 
due to blockade of lysososmal calcium release, we performed a rescue experiment in 
TRPML1 knockdown Human Umbilical Vein Endothelial Cells (HUVEC) (Figure 2.2 a) 
and HEK293T (Figure 2.2 b) using thapsigargin, a sarco/endoplasmic reticulum Ca2+-
ATPase inhibitor that increases cytosolic calcium concentrations (27). Indeed, the 
inhibition of mTORC1 activity by TRPML1 knockdown was rescued by thapsigargin, 
suggesting that mTORC1 inhibition was due, in large part, to the lack of lysosomal 
calcium release. Furthermore, we determined the phosphorylation of S6K in normal 
human fibroblasts (TRPML1 +/+) and fibroblasts from a mucolipidosis IV patient 
(TRPML1 -/-). Compared with TRPML1 +/+ human fibroblasts, TRPML1 -/- cells 
showed decreased phosphorylation of S6K. However, the treatment of thapsigargin fully 
restored the phosphorylation of S6K (Figure 2.2 c). 
          In order to investigate whether amino acid can rescue mTORC1 inhibition caused 
by depletion of TRPML1, we firstly knocked down TRPML1 in HEK293T cells, then 
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starved the cells with leucine-free medium and restimulated cells with leucin. As shown 
in figure 2.3 a, knocking down TRPML1 attenuated the activation of mTORC1 by 
leucine. In addition, compared with TRPML1 +/+ human fibroblasts, TRPML1 -/- cells 
showed decreased phosphorylation of S6K. Interestingly, this inhibition was partially 
reversed by leucine compared with that in wild type cells (Figure 2.3 b). Figure 2.2c and 
2.3b suggest that in mammalian cells, the decrease in mTORC1 activity in TRPML1 
mutant cells is not only due to the incomplete autophagy that has been reported in 
Drosophila (22). Have shown that depletion of TRPML1 attenuates the activation of 
mTORC1 by leucine, we next investigate whether overexpression of Rag GTPase can 
rescue this attenuation. HEK293T cells were transfected with constitutively active 
RagAQ66L and RagCS75L mutants and starved with leucine. The result shows that 
overexpression of constitutively active RagA or RagC were not able to fully rescue 
mTORC1 inhibition caused by depletion of TRPML1 (Figure 2.3 c), indicating that the 
regulation of mTORC1 by TRPML1 acts parallel to amino acid/Rag GTPase axis. 
          Next, in order to investigate whether insulin can rescue the effect of depletion of 
TRPML1, HEK293T cells were transduced with lentivirus carrying shRNA targeting 
human TRPML1 gene, and then the cells were starved with serum, and restimulated with 
insulin. As shown in Figure 2.4, depletion of TRPML1 attenuated the activation of 
mTORC1 signaling by insulin, indicating that the regulation of mTORC1 by TRPML1 is 
parallel to the regulation by insulin. 
          In addition, knockdown of other lysosomal channels, such as TPC2 and P2X4, did 
not significantly inhibit mTORC1 signaling (Figure 2.5), indicating that the decreased 
mTOR activity upon TRPML1 knockdown was not due to the dysregulation of the 
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structure of the endolysosmal system, and as one of the lysosomal calcium channels, 
TRPML1 may play a more dominant role in the regulation of mTORC1 signaling. 
          Having shown that TRPML1-mediated lysosomal calcium release is necessary for 
mTORC1 activity, we then turned to the reciprocal question of whether an increase in 
lysosomal calcium release through TRPML1 could stimulate mTORC1. Thus, HEK293T 
cells were transfected with expression plasmids for EGFP-TRPML1 and its non-
conducting pore mutant (D471K/D472K) EGFP-TRPML1 (KK), respectively. The 
phosphorylation of S6K was slightly but significantly increased by overexpression of 
wild type TRPML1 but not the non-conducting pore mutant TRPML1 (KK) (Figure 2.6), 
suggesting that TRPML1 positively regulates mTORC1 pathway. 
          MLSA1 has been reported to be a TRPML1 agonist that stimulates the lysosomal 
Ca2+ release through TRPML1(18, 28). Therefore, in order to test whether MLSA1 also 
activates mTORC1 pathway, we treated HEK293T cells with different concentrations of 
MLSA1. The phosphorylation of S6K was increased by MLSA1 in a dose-dependent 
manner (Figure 2.7 a). In order to investigate whether this activation was due to the 
boost of TRPML1, we compared the effect of MLSA1 to mTORC1 between wild type 
and TRPML1 knockdown HEK293T cell. MLSA1 failed to increase the phosphorylation 
of S6K in the cells transduced with lentiviral TRPML1 shRNA, or pretreated with 
bafilomycin A1 or Glycyl-L-phenylalanine 2-naphthylamide (GPN), suggesting that the 
increase in S6K phosphorylation induced by MLSA1was mediated by TRPML1 (Figure 
2.7 b, c). 
          Upon amino acids stimulation, mTOR translocated from the cytosol to the 
lysosome, colocalizing with EGFP-TRPML1 (Figure 2.8), indicating that the activation 
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of TRPML1 acted independently of the translocation of mTORC1 induced by amino 
acids.  
          The upregulated TRPML1 has been reported to promote autophagy (22, 29, 30). To 
determine if activation of mTORC1 in response to TRPML1 overexpression was due to 
up-regulated autophagy, we overexpressed constitutively active Rab7A (Q67L) and 
dominant negative Rab7A (T22N) in HEK293T cells (31, 32). As shown in revised 
Figure 2.9, neither overexpression of constitutively active nor dominant negative Rab7A 
affected mTORC1 signaling, while overexpression of TRPML1 plus MLSA1 treatment 
stimulated the phosphorylation of S6K, suggesting that the activated mTORC1 by 








Figure 2.1: Depletion of TRPML1 inhibits mTORC1 signaling pathway in 
HEK293T cells.  
HEK293T cells were transduced with lentiviral scrambled shRNA (Scr) and shRNA 
targeting human TRPML1 (Sh1 and Sh2), respectively. To assess the knockdown 
efficiency, a fraction of transduced cells were transfected with EGFP-TRPML1. After 24 
h, transfected or untransfected cells were lysed and subjected to immunoblotting.  
Untransfected cells were used to detect p-S6K, S6K and p-Akt, and transfected cells were 
used to detect GFP and GAPDH. RT-qPCR was also performed to evaluate the 
knockdown efficiency (right panel) (mean ± s.d., n = 2 independent experiments).  
  
Figure 2.2: Inhibition of mTORC1 by TRPML1 depletion is rescued by 
thapsigargin.  
Scrambled shRNA or TRPML1 shRNA-transduced (a) HUVEC or (b) HEK293T cells 
were treated with vehicle control or thapsigargin (5 μM) for an additional 2 h. Cells were 
lysed and subjected to immunoblotting. Knockdown efficiency was assessed by RT-
qPCR (right panels). The right two panels of plots in (a) show the percentage of p-S6K 
and p-4EBP1 levels compared with scramble shRNA transduced vehicle control treated 
HUVEC normalized by GAPDH loading control (mean ± s.d., n = 2 independent 
experiments). (c) Healthy human fibroblast or mucolipidosis IV patient’s fibroblasts 
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(TRPML-/-) were treated with vehicle control or thapsigargin (5 µM) for 2 h, respectively. 
Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-
S6K level compared with vehicle control treated wild type human fibroblasts normalized 
by total S6K control. (mean ± s.d. for n = 3 independent experiments). 
  
Figure 2.3: Depletion of TRPML1 attenuates mTORC1 activation by leucine.  
(a) Scrambled shRNA or TRPML1 shRNA transduced HEK293T cells were deprived for 
3 h of leucine, and, where indicated, were stimulated with 52 μg/ml leucine for 10 min. 
Simultaneously, another fraction of scrambled shRNA or TRPML1 shRNA-transduced 
cells were transfected with EGFP-TRPML1 for 24 h. Cells were lysed and subjected to 
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immunoblotting. The plot shows the percentage of p-S6K levels compared with scramble 
shRNA transduced leucine starved HEK293T cells normalized by total S6K control 
(mean ± s.d., n = 2 independent experiments, respectively). (b) Wild type and 
mucolipidosis IV patient’s fibroblasts (TRPML-/-) were treated with vehicle control or 
leucine for 10 min. Cells were lysed and subjected to immunoblotting. The plot shows the 
percentage of p-S6K level compared with vehicle control treated TRPML-/- human 
fibroblasts normalized by total S6K control. (mean ± s.d. for n = 2 independent 
experiments). (c) Scrambled shRNA or TRPML1 shRNA-transduced HEK293T cells 
were transfected with Rag AQ66A or Rag CS75L for 24 h. Cells were lysed and 
subjected to immunoblotting. The plot shows the percentage of p-S6K level compared 
with scramble shRNA transduced empty vector transfected HEK293T cells normalized 




Figure 2.4: Depletion of TRPML1 attenuates mTORC1 activation by insulin.  
Scrambled shRNA or TRPML1 shRNA transduced HEK293T cells were deprived for 24 
h of serum and, where indicated, were stimulated with 600 nM insulin for 10 min. 
Simultaneously, another fraction of scrambled shRNA or TRPML1 shRNA-transduced 
cells were transfected with EGFP-TRPML1 for 24 h. Cells were lysed and subjected to 
immunoblotting. The plots show the percentage of p-S6K levels compared with scramble 
shRNA transduced serum starved HEK293T cells normalized by total S6K control (mean 
± s.d., n = 2 independent experiments, respectively).  
 
Figure 2.5: Depletion of TPC2 or P2X4 does not affect mTORC1 signaling pathway.  
Lentivirus carrying scrambled shRNA, TRPML1 shRNA, TPC2 shRNA or P2X4 shRNA 
transduced HEK293T cells were lysed and subjected to immunoblotting. RT-qPCR 







Figure 2.6: Overexpression of wild type TRPML1 but not dead mutant activates 
mTORC1 signaling pathway.  
HEK293T cells (80% confluency) were transfected with EGFP vector, EGFP-TRPML1 
or its non-conducting pore mutant (D471K/D472K) EGFP-TRPML1 (KK) for 20 h. Cells 
were lysed and subjected to immunoblotting. The plot shows the percentage of p-S6K 
levels compared with vector transfected cells normalized by total S6K control (mean ± 
s.d., n = 3 independent experiments). 
 
Figure 2.7: Pharmacological stimulation of TRPML1 activates mTORC1 pathway.  
(a) HEK293T cells were treated with different concentrations of ML-SA1 for 3 h. Cells 
were lysed and subjected to immunoblotting. The plot shows the dose-response curve of 
ML-SA1 normalized by total S6K. (b) Scrambled shRNA or TRPML1 shRNA 
transduced HEK293T cells were treated with varying concentrations of MLSA1 for 3 h. 
Cells were lysed and subjected to immunoblotting. The plot shows the percentage of p-
S6K levels compared with scramble shRNA transduced vehicle control treated 293T cells 
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normalized by GAPDH loading control (mean ± s.d., n = 3 independent experiments). (c) 
HEK293T cells were pretreated with bafilomycin A1 (1 µM) or GPN (200 µM) for 1 h, 
followed by treatment with or without MLSA1 for an additional 1.5 h. Cells were lysed 
and subjected to immunoblotting. The plot shows the percentage of p-S6K levels 
compared with vehicle control normalized by GAPDH loading control (mean ± s.d., n = 3 
independent experiments). * p < 0.05, ** p < 0.01, n.s. no significant difference.  
  
Figure 2.8: Colocalization of EGFP-TRPML1 and mTOR.  
HEK293T cells were transfected with EGFP-TRPML1 expression plasmid. After 18 
hours, cells were treated with MLSA1 (15 μM) for 1 hour, and starved with amino acids 
for 1 hour, or starved with amino acids for 1 hour and restimulated with amino acids for 
15 min. Cells were fixed, stained with anti-mTOR antibody and images were captured 
using a Zeiss LSM510 confocal microscope. 
 
 
Figure 2.9: Effects of constitutively active or dominant negative Rab 7A.  
HEK293T cells were transfected with EGFP-ML1, EGFP-Rab7A (Q67L) or EGFP-
Rab7A (T22N). After 19 hours, the cells transfected with EGFP-ML1 were treated with 
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Calcium and CaM are required for activation of mTORC1, and the regulation of 
mTORC1 by cytosolic calcium and CaM occurs proximal to mTORC1 itself 
          Both intracellular calcium and CaM have been reported to be required for 
mTORC1 activity (10-14). We thus treated HEK293T cells with the cytosolic Ca2+ 
chelator BAPTA-AM (BAPTA) or the CaM antagonists W-7 and calmidazolium 
(CMDZ). In agreement with previous studies (11, 13, 33, 34), we observed that CMDZ, 
W-7 and BAPTA inhibited phosphorylation of S6K in a dose-dependent manner with 
IC50 values of 3.96 ± 1.30 µM, 21.59 ± 1.81 µM and 10.36 ± 0.59 µM, respectively 
(Figure 2.10). In comparison to S6K, phosphorylation of Akt (S473), the substrate of 
mTORC2, was also inhibited by CMDZ and W-7, but at much higher concentrations 
(EC50 values of 27.21 ± 9.82 µM and 45.91 ± 9.61 µM, respectively) compared with that 
of p-S6K, while BAPTA did not show appreciable inhibition to p-Akt (S473) (Figure 
2.10 c). In addition, CMDZ and BAPTA also showed potent inhibitory effect on 
mTORC1 signaling pathway in HUVEC and A549 cells (Figure 2.10 d, e), suggesting 
that the inhibition of mTORC1 by disruption of Ca2+/CaM is also observed in primary 
and other cancer cells. 
          Next, we investigated how fast mTORC1 and mTORC2 responded to BAPTA or 
CMDZ. As shown in Figure 2.11, both CMDZ and BAPTA caused appreciable 
inhibition of mTORC1 activity within 0.5-1 hour as judged by the phosphorylation of 
S6K and 4EBP1. In contrast, the phosphorylation of Akt (T308) and its substrate, mTOR 
(S2448), was not significantly affected by CMDZ until 6 hours post treatment. In 
addition, CMDZ did not cause significant inhibition of phosphorylation of Akt (S473) 
until 3 hours after treatment, indicating that the response of mTORC2 to the CaM 
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antagonist has a much slower onset than that of mTORC1 (Figure 2.11 a left panel, b 
and c). Although the onset of the effect of BAPTA on 4EBP1 phosphorylation was 
slightly slower than that of CMDZ, BAPTA did not significantly affect the 
phosphorylation of either Akt (S473, T308) or mTOR even after 6 hours (Figure 2.11 a 
right panel, d and e). These results suggest that CaM regulates both mTORC1 and 
mTORC2, but the two complexes differ in their sensitivity to CaM and calcium. 
Interestingly, after a 6-hour treatment with BAPTA, the inhibition to phosphorylation of 
S6K and 4EBP1 was partially reversed (Figure 2.11 a and d), which is consistent with a 
previous report that with the treatment time of BAPTA, a gradual increase of intracellular 
Ca2+ was seen (35). The relatively short time required for CMDZ and BAPTA to exert 
their effects on mTORC1 and their faster onset than those on mTORC2 suggested that the 
inhibition of mTORC1 likely occurred independently of its upstream signaling events, 
such as phosphorylation of Akt (T308). 
          To further explore the level at which Ca2+ and CaM regulate mTORC1 signaling, 
we determined the effects of CMDZ and BAPTA on mTORC1 activation in response to 
various upstream activating stimuli of mTORC1. Similar to previous observations (13), 
we found that leucine-stimulated mTORC1 activation was inhibited by BAPTA and 
CMDZ (Figure 2.12 a, Lanes 4 vs. 2 and 6 vs. 2). The activation of mTORC1 by leucine 
has been shown to be mediated by the small GTPases RagA/B and RagC/D (8), and 
overexpression of constitutively active RagAQ66L/RagCS75N can bypass leucine to activate 
mTORC1. We found that activation of mTORC1 in response to either RagAQ66L or 
RagCS75N was still inhibited by CMDZ (Figure 2.12 b).            
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          Next, we determined whether activation of mTORC1 by insulin was also sensitive 
to CaM blockade. Although insulin strongly increased the phosphorylation of Akt (T308) 
(Figure 2.13 a), the mTORC1 activity remained sensitive to CMDZ as well as BAPTA-
AM (Figure 2.13 a, Lanes 4 and 6). It has been reported that mTOR is directly bound to 
and activated by Rheb-GTP (36). Thus, we used HEK293T, HUVEC and A549 to 
produce stable cell lines overexpressing constitutively active RhebN153T as previously 
described (37), and determined their sensitivity to BAPTA and CMDZ. RhebN153T-
induced phosphorylation of S6K remained sensitive to inhibition by BAPTA and CMDZ 
in HEK293T, HUVEC and A549 cells (Figure 2.13 b, c, d, e). Together, these results 
suggested that the site of regulation of mTORC1 by Ca2+ and CaM lies proximal to 
mTORC1 itself.             
 
Figure 2.10: Calmodulin antagonists and cytosolic calcium chelator inhibit 
mTORC1 pathway in a dose-dependent manner.  
Effects of calmodulin antagonist (a) calmidazolium (CMDZ), (b) W-7 and (c) cytosolic 
Ca2+ chelator BAPTA-AM on phosphorylation state of S6K (T389) and Akt (S473).  
HEK293T cells were treated with different concentrations of indicated compound for 1 hr. 
The phosphorylation state of S6K and Akt was analyzed by immunoblotting. The plots 
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show the dose-response curve of CMDZ, W-7 and BAPTA normalized by total S6K, 
respectively. HUVEC (d) and A549 (e) cells were treated with different concentrations of 




Figure 2.11: Calmodulin antagonist and cytosolic calcium chelator inhibit mTORC1 
pathway within a short time treatment.  
(a) Effects of 10 μM CaM antagonist calmidazolium (CMDZ) or 25 μM cytosolic Ca2+
chelator BAPTA-AM (BAPTA) on the phosphorylation of different proteins of the 
mTOR signaling pathway at different time points. The percentage of p-S6K (b and d) 
and p-Akt (S473) (c and e) levels compared with 0 min treated 293T cells normalized by 
total S6K and total Akt control, respectively (mean ± s.d., n = 3 independent 
experiments). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0,0001. 
 
Figure 2.12: Calmodulin antagonist and cytosolic calcium chelator inhibit the 
activation of mTORC1 through amino acid/Rag GTPase axis.  
(a) Effects of CMDZ (10 μM) or BAPTA-AM (25 μM) on the phosphorylation of 
indicated proteins in response to deprivation and stimulation with leucine. Cell lysates 
were prepared from HEK293T cells deprived for 3 h of leucine and, where indicated, 
stimulated with 52 μg/ml leucine for 10 min. CMDZ (10 μM) or BAPTA-AM (25 μM) 
was added 1 h prior to cell harvesting. The plot shows the percentage of p-S6K levels 
compared with vehicle control treated leucine starved HEK293T cells normalized by total 
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S6K control (mean ± s.d., n = 3 independent experiments, respectively). (b) Effects of 
CMDZ (10 µM) on the phosphorylation of S6K in HEK293T cells transfected with 
constitutively active RagA or RagC in expression vectors. Cell lysates were prepared and 
subjected to immunoblotting. The plot shows the percentage of p-S6K levels compared 
with vector transfected vehicle control treated 293T cells normalized by GAPDH loading 
control (mean ± s.d., n = 3 independent experiments).  
  
Figure 2.13: Calmodulin antagonist and cytosolic calcium chelator inhibit the 
activation of mTORC1 through insulin/Rheb axis.  
(a) Effects of CMDZ (10 μM) or BAPTA-AM (25 μM) on the phosphorylation of 
indicated proteins in response to deprivation and stimulation with insulin. Cell lysates 
were prepared from HEK293T cells deprived for 24 h of serum and, where indicated, 
stimulated with 600 nM insulin for 10 min. CMDZ (10 μM) or BAPTA-AM (25 μM) was 
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added 1 h prior to cell harvesting. The plot shows the percentage of p-S6K levels 
compared with vehicle control treated serum starved HEK293T cells normalized by total 
S6K control (mean ± s.d., n = 3 independent experiments, respectively). (b) and (c) 
Effects of 25 µM BAPTA-AM (b) and 10 µM CMDZ (c) on the phosphorylation state of 
S6K in HEK293T cells stably expressing constitutively active Rheb as indicated. 
HEK293T cells were transduced with lentiviral FLAG-tagged RhebN153T, and treated with 
indicated compounds for 1 h. Cell lysates were prepared and used for immunoblotting. 
The plots show the percentage of p-S6K levels compared with vehicle control treated 
empty lentiviral vector transduced 293T cells normalized by total S6K control (mean ± 
s.d., n = 2 independent experiments). HUVEC (d) and A549 (e) cells were transduced 
with lentivirus carrying constitutively active RhebN153T. The transduced cells were treated 
with BAPTA or CMDZ for 1 h. The phosphorylation state of S6K was analyzed by 
immunoblotting. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0,0001. 
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CaM interacts with mTOR 
          First, we determined whether CaM intereacted with mTORC1. As shown in Figure 
2.14, CaM could pull down mTOR and raptor, but not PRAS40, in a Ca2+-dependent 
manner, and the binding is sensitive to detergents and CaM antagonist W-7. CaM has 
been previously reported to indirectly interact with mTORC1, and human vacuolar 
protein sorting 34 (hVps34) was shown to mediate the interaction between CaM and 
mTORC1 in HeLa cells (13). To our surprise, when hVps34 was knocked down in 
HEK293T cells, binding of CaM to mTOR was not affected (Figure 2.15), neither was 
the sensitivity of mTORC1 to CaM (Figure 2.16), ruling out hVps34 as a mediator of 
CaM-mTOR interaction in HEK293T cells. These results raised the possibility that CaM 
may directly interact with a subunit of the mTORC1 complex, thereby regulating its 
kinase activity. However, Ca2+ did not affect the assembly of mTORC1 complex (Figure 
2.17), suggesting that one of the interactions of CaM sepharose with mTOR and raptor 
could be indirect. To identify the subunit in mTORC1 that interacts with CaM, we 
knocked down raptor and mTOR, respectively, and determined the remaining interaction 
between each subunit and CaM sepharose (Figure 2.15). Knockdown of raptor had no 
effect on the pulldown of mTOR by CaM sepharose. In contrast, knockdown of mTOR 
significantly reduced the binding of raptor as well as mTOR to CaM (Figure 2.15), 
suggesting that the interaction between mTOR and CaM is independent of raptor. 
  
Figure 2.14: Calmodulin interacts with mTORC1 in a Ca2+-dependent manner.  
(a) Endogenous mTORC1 was pulled down by CaM sepharose in a Ca2+-dependent 
manner. HEK293T cells were lysed in Triton X-100, NP-40 or CHAPS buffer, and the 
lysates were incubated with CaM sepharose in the presence of CaCl2 (1 mM) or EGTA (5 
mM). The precipitates were analyzed by immunoblotting. (b) The interaction between 
CaM and mTOR is inhibited by the CaM antagonist W-7. Cell lysates were prepared 
from HEK293T cells in CHAPS buffer, and endogenous mTOR was precipitated by CaM 
sepharose in the presence of W-7 or vehicle control. 
Figure 2.15: CaM interacts with mTOR independent of hVps34 or raptor.  
Cell lysates were prepared from HEK293T cells transduced with lentiviral shRNAs 
targeting human mTOR, raptor, hVps34 or scrambled shRNA, followed by CaM 
sepharose precipitation in the presence of CaCl2 (1 mM) or EGTA (5 mM). The cell 
lysates and precipitates were analyzed by immunoblotting to detect the indicated proteins. 
  
Figure 2.16: Effects of calmidazolium (CMDZ) on hVps34 depleted cells.  
(a) HEK 293T cells were transduced with lentivirus carrying scramble shRNA or shRNA 
targeting hVps34. 96 hours after puromycin selection, cells were treated with vehicle 
control or CMDZ (10 μM) for 1 hour. (b) The same cells in (a) were starved with amino 
acids for 1 hours, and re-stimulated with amino acids for 10 min. Cells were lysed and 




Figure 2.17: The presence or absence of Ca2+ does not affect the association of 
mTORC1.  
Cell lysates were prepared from HEK293T in CHAPS buffer, and endogenous mTORC1 
was immunoprecipitated by mTOR antibody. Rabbit IgG was used as mock 
immunoprecipitation.  
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Ca2+ and CaM activate the mTORC1 kinase activity in vitro 
          Having shown that CaM-binding fragment of mTOR (TRD3) exerted a dominant 
negative effect on mTORC1 activity in cells, we asked the question of whether CaM and 
Ca2+ had a direct effect on the intrinsic kinase activity of isolated mTORC1 complex in 
vitro. Thus, endogenous mTORC1 complex was immunoprecipitated by an anti-raptor 
antibody, and an in vitro kinase assay was performed using purified recombinant 4EBP1 
as a substrate (38). As shown in Figure 2.18 a, the phosphorylation of 4EBP1 by 
immunoprecipitated mTORC1 complex was significantly increased in the presence of 
both CaCl2 (0.2 mM) and CaM (2 µM), but not CaM alone, indicating that CaM activates 
mTORC1 kinase activity in vitro in a Ca2+-dependent manner (Figure 2.18 a, top left 
and top right panels, Lanes 1-3, respectively). Importantly, the activation of mTORC1 
by Ca2+/CaM was inhibited by Torin 1 (Figure 2.18 a, top left panel, Lane 4), a TOR 
kinase inhibitor, and CMDZ (Figure 2.18 a, top right panel, Lane 4), indicating that the 
phosphorylation of 4EBP1 was dependent on TOR kinase activity and CaM. Similar 
results were obtained from the in vitro kinase assay using purified recombinant S6K as 
the substrate (Figure 2.18 b). These results demonstrated that CaM binding to mTOR 
leads to the stimulation of kinase activity of the mTORC1 complex.  
  
 
Figure 2.18: Calmodulin interacts with mTORC1 in a Ca2+-dependent manner.  
Cell lysates were prepared from HEK293T cells in CHAPS buffer, and endogenous 
mTORC1 was immunoprecipitated by a raptor antibody. ATP (250 μM), Torin1 (100 
nM), CMDZ (8 μM), CaM (2 μM) or/and CaCl2 (0.2 mM) were added into the kinase 
reaction as indicated. Phosphorylation of 4EBP1 (a) and S6K (b) were detected by 
immunoblotting. The plots show the fold of change of phosphorylation of 4EBP1 (a) or 
S6K (b) compared with control group (first lane) normalized by total GST-tagged protein 
control. (mean ± s.d., n = 6 and 5 independent experiments, respectively). 
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2.5 Discussion 
     The work described in this manuscript reveals a novel mechanism of regulation of 
mTORC1 by lysosomal calcium and CaM, shedding new light on the mTOR signaling 
pathway (Figure 2.19). In the current model of mTORC1 activation (39-42), growth 
factors, energy, and other inputs signal to mTORC1 primarily through the TSC-Rheb axis; 
amino acids act by regulating the nucleotide state of the heterodimeric Rag GTPases and 
promoting the translocation of mTORC1 onto lysosomes, where it interacts with and 
becomes activated by lysosomally-localized, GTP-bound Rheb (9). Our results have 
uncovered another role of lysosomal localization of mTORC1, i.e., to receive localized 
lysosomal calcium stimulation. Integrating our previous observations (16) and the results 
from the present study, we propose an addition to the current model of mTOR signaling 
pathway: upon the translocation of mTORC1 onto the lysosome, properly released 
lysosomal calcium enriches local Ca2+ concentration, prompting Ca2+ binding to a local 
population of CaM, which in turn binds mTORC1 and stimulates the kinase activity of 
the mTORC1 complex.  
 The depletion of the homolog of TRPML1, TRPML in Drosophila, results in 
decreased TORC1 signaling, which was attributed to incomplete autophagy, and was 
completely reversed by feeding fly larvae with a high-protein diet (22, 23).  However, we 
showed that in TRPML1-knockdown mammalian cells or mucolipidosis IV human 
fibroblasts, the inhibited mTORC1 signaling was only partially reversed by leucine or 
overexpression of constitutively active Rag GTPase, suggesting that there is a difference 
in the mechanisms of regulation of mTOR by Ca2+/CaM between mammalian and fly 
cells. Interestingly, thapsigargin, which increases cytosolic Ca2+, could completely 
	   74	  
restore phosphorylation of S6K in TRPML1 deficient cells to the control level. Given that 
increased cytosolic Ca2+ also positively regulates the Ca2+-dependent fusion of late-
endosomes and autophagosomes to lysosomes (17, 22, 43), the rescue effect of 
thapsigargin might be due to the combined effects of autophagy as well as the direct 
stimulation of mTORC1 by Ca2+/CaM in mammalian cells. On the other hand, TRPML1 
is significantly upregulated under amino acids starvation (29), when mTORC1 
dissociates from the lysosomal surface and becomes inactive, indicating that mTORC1 
and TRPML1 may form reciprocal regulation loop. In addition, it has been recently 
reported that under starvation, lysosomal Ca2+ release through TRPML1 activates local 
calcineurin, a Ca2+, CaM-dependent protein phosphatase, which dephosphorylates TFEB 
and promotes its nuclear translocation as well as regulates lysosomal biogenesis (30), 
suggesting another local function of lysosomal Ca2+. 
          Our model of regulation of mTORC1 by Ca2+ and CaM differs from that proposed 
in a previous report (13), even though some of the experimental observations are in 
agreement. Similar to previous reports (11, 13, 33), we found that mTORC1 activity is 
sensitive to inhibition by BAPTA-AM and CaM antagonist CMDZ (Figure 3), suggesting 
that both intracellular calcium and CaM are required for mTORC1 activation. However, 
the precise mechanism of regulation of mTORC1 by calcium and CaM is distinct in our 
new model. First, we demonstrated that the lysosomal pool of calcium plays a unique and 
critical role in mTORC1 activation in mammalian cells. In earlier studies, however, the 
sources of calcium have been only suggested to be extracellular (10, 13) or conventional 
intracellular calcium stores such as the ER (11, 33, 34). Second, a previous study showed 
the CaM associates with mTORC1 complex through hVps34, and calcium and CaM 
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activate mTORC1 via hVps34 activation (13). In an independent study, it was shown that 
hVps15, but not Ca2+/CaM, activates hVps34 (15). Similarly, we also found that 
knockdown of hVps34 had no effect on the interaction between CaM and mTORC1 in 
HEK293T cells, ruling out involvement of hVps34 in the regulation of mTORC1 via 
Ca2+/CaM, at least in this cell type. We surmise that most of the previous results 
implicating calcium or CaM in the regulation of mTORC1 may be explained by our 
current model. 
          In previous studies, in vitro kinase assay of mTORC1 used EDTA in 
immunoprecipitation buffer (24, 44), which precluded the detection of any regulatory 
effect of calcium and CaM. By performing the mTOR kinase assay in the absence or 
presence of calcium and CaM in vitro, we were able to observe a dramatic activation of 
mTORC1 by calcium and CaM, revealing the functional consequence of the binding of 
CaM to mTOR--activation of its intrinsic kinase activity. As such, mTOR is a new type 
of atypical CaM-dependent kinase. The newly uncovered roles of lysosomal calcium and 
CaM in the regulation of mTOR signaling not only fill a gap in our understanding of this 
fundamental signaling pathway, but also offer new molecular targets for discovering and 
developing novel mTOR inhibitors. 
  
Figure 2.19: Proposed model of regulation of mTORC1 by TRPML1, lysosomal 
calcium and CaM.  
Upon the translocation of mTORC1 onto the lysosome through binding to GTP-Rheb, 
lysosomal Ca2+ released through TRPML1 enriches the local Ca2+ concentration, 
prompting the binding to and activation of CaM, which in turn interacts with mTORC1 
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Chapter 3: Divergence of antiangiogenic activity and 
hepatotoxicity of different stereoisomers of itraconazole 
3.1 Abstract 
          In Chapter 2, I described a fundamental study of the regulation of mTOR 
signaling pathway by discovering that lysosomal calcium and calmodulin are required for 
mTORC1 activation using the methods involving chemical biology and genetic 
manipulation. In this chapter, I will describe a chemical biology study to study the 
divergence of antiangiogenesis activity and hepatotoxicity of different stereoisomers of 
itraconazole. Itraconazole is a triazole antifungal drug that has recently been found to 
inhibit angiogenesis. Itraconazole is a relatively well-tolerated drug but shows 
hepatotoxicity in a small subset of patients. Itraconazole contains three chiral centers and 
the commercial itraconazole is composed of four cis-stereoisomers (named IT-A, IT-B, 
IT-C, and IT-D). However, whether the stereoisomers of itraconazole are differ in their 
antiangiogenic activity and hepatotoxicity remains unknown. Here, we assessed in vitro 
antiangiogenic activity of itraconazole and each stereoisomer using human umbilical vein 
endothelial cell (HUVEC) proliferation and tube formation assays. We also determined 
their hepatotoxicity using primary human hepatocytes in vitro and a mouse model in vivo. 
Mouse Matrigel plug and tumor xenograft models were used to evaluate in vivo 
antiangiogenic and antitumor activities of the stereoisomers. Of the four stereoisomers 
contained in commercial itraconazole, we found that IT-A (2S,4R,20R) and IT-C 
(2S,4R,20S) were more potent for inhibition of angiogenesis than IT-B (2R,4S,20R) and 
IT-D (2R,4S,20S). Interestingly, IT-A and IT-B were more hepatotoxic than IT-C and IT-
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D. In mouse models, IT-C showed more potent antiangiogenic/antitumor activity with 
lower hepatotoxicity compared with itraconazole and IT-A. These results demonstrate the 
segregation of influence of stereochemistry at different positions of itraconazole on its 
antiangiogenic activity and hepatotoxicity, with the 2 and 4 positions affecting the former 
and the 20 position affecting the latter. They also suggest that IT-C may be superior to 
the racemic mixture of itraconazole as an anticancer drug candidate due to its lower 
hepatotoxicity and improved antiangiogenic activity. 
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ABBREVIATIONS 
HUVEC, human umbilical vein endothelial cells; mTOR, mechanistic target of 
rapamycin; mTORC1, mTOR complex 1; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; S6K, ribosomal s6 kinase; VEGF, vascular endothelial growth factor; 
NPC, Niemann-Pick Disease Type C; CYP3A4, cytochrome P450 3A4; ALT, alanine 
aminotransaminase; LDL, low-density lipoprotein.  
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3.2 Introduction 
          Angiogenesis, the formation of new blood vessels from preexisting vasculature, has 
been shown to play a critical role in both normal physiologic and pathologic processes. It 
is essential during development and wound healing, and is tightly regulated by 
endogenous pro- and antiangiogenic factors. It has also been implicated in a number of 
diseases including cancer, rheumatoid arthritis and macular degeneration (1-3). Since the 
angiogenesis hypothesis was first proposed by Judah Folkman in 1971 (4), a number of 
angiogenesis inhibitors have been discovered and developed into antiangiogenic drugs (5-
7). A monoclonal antibody against VEGF, bevacizumab, was first approved by the FDA 
in 2004 for the treatment of metastatic colon cancer in combination with standard 
chemotherapy. Subsequently, several small-molecule angiogenesis inhibitors have been 
entered the clinic, including sorafenib (Nexavar), sunitinib (Sutent), and pazopanib 
(Votrient). However, most of these small-molecule antiangiogenic drugs are kinase 
inhibitors that lack specificity or lead to a high frequency of drug resistance (8-10), 
necessitating the development of small-molecule angiogenesis inhibitors with novel 
mechanisms of action. In an effort to accelerate drug discovery and development, we 
assembled the Johns Hopkins Drug Library over a decade ago and screened it for new 
antiangiogenic activity among existing drugs using a proliferation assay with primary 
human umbilical vein endothelial cells (HUVEC). Among the most interesting hits was 
the antifungal drug itraconazole (11). Interestingly, itraconazole was also found to be an 
inhibitor of the hedgehog signaling pathway in a separate screen, rendering itraconazole a 
novel anticancer drug candidate capable of inhibiting the growth of both tumor 
vasculature and tumor cells themselves (12). A series of tests of itraconazole in 
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preclinical angiogenesis and cancer models confirmed the antiangiogenic and anticancer 
activity of itraconazole in vivo (11-13). On the basis of these promising preclinical 
results, itraconazole entered multiple Phase II human clinical studies for treating different 
types of cancer. (http://www.clinicaltrials.gov/). Positive clinical results have been 
reported for advanced lung cancer, metastatic prostate cancer, and basal cell 
carcinoma (14-16). Moreover, itraconazole was found to increase progression or overall 
survival among late-stage ovarian, triplenegative breast and metastatic pancreatic cancer 
patients upon retrospective analysis of previous clinical data (17-19). Together, 
these encouraging results strongly suggest that itraconazole is a promising new anticancer 
drug lead. Although the precise mechanism for the antiangiogenic and anti-hedgehog 
activities remains unknown, preliminary evidence suggests that the mode of action of 
itraconazole is distinct from any other known inhibitors of angiogenesis or the hedgehog 
signaling pathway. Early on, we ruled out the cholesterol biosynthetic enzyme, lanosterol 
14a-demethylase, which mediates the antifungal activity of itraconazole, as the relevant 
target for its antiangiogenic activity (11). Subsequently, we serendipitously discovered 
that itraconazole blocks the traffic of cholesterol and likely lipids out of the lysosome, 
causing a phenotype similar to Niemann-Pick Disease Type C (NPC) in endothelial cells. 
We also found that itraconazole is a potent inhibitor of the mTOR pathway in endothelial 
cells (20). Importantly, the blockade of cholesterol trafficking through the endolysosome 
can only partially explain the inhibition of mTOR by itraconazole, suggesting that there 
exist unidentified molecular target(s) for itraconazole. Similarly, the mechanism 
underlying the inhibition of hedgehog signaling also remains unclear, even though it has 
been shown to block the translocation of Smoothened from intracellular vesicles into the 
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primary cilium (12). Using a number of synthetic analogs of itraconazole, we explored 
the structure-activity relationship of itraconazole for its two distinct activities and found 
no correlation between the two, further suggesting that the antiangiogenic and anti-
hedgehog activity of itraconazole are likely to be mediated by different molecular 
mechanisms (21). Itraconazole has been widely used to treat fungal infections. 
Although itraconazole is known to be relatively well tolerated, about 7% of patients who 
received the drug experience hepatotoxicity (22). In addition to lanosterol 14 alpha-
demethylase (23), itraconazole is also known to be a potent inhibitor of human liver 
cytochrome P450 3A4 (CYP3A4), accounting for its extensive drug–drug interactions 
with other medications (24). It is believed that the effect of itraconazole on CYP3A4 is 
responsible for the human hepatotoxicity (25). The commercial itraconazole consists of 
four cis-stereoisomers of itraconazole, including IT-A (2S,4R,2’R), IT-B (2R,4S,2’R), 
IT-C (2S,4R,2’S), and IT-D (2R,4S,2’S). All four isomers are known to be ligands of 
CYP3A4 (26). However, only IT-B and IT-D among the four isomers were metabolized 
by CYP3A4 (26). To assess the antiangiogenic activity of the different stereoisomers, we 
previously synthesized each of cis-stereoisomers and determined their effects on both 
fungi and endothelial cells (27). In this study, we conducted a large-scale purification of 
each stereoisomer from the racemic itraconazole mixture using the preparative 
supercritical fluid chromatography (SFC) and obtained gram quantities of each purified 
stereoisomer. Using the purified stereoisomers, we compared the antiangiogenic activity 
and hepatotoxicity of each stereoisomer of itraconazole and the racemic itraconazole both 
in vitro and in vivo. We found that ITA and IT-C are more potent at inhibiting 
angiogenesis compared to the others, whereas IT-C and IT-D are less hepatotoxic 
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compared to IT-A, IT-B and racemic itraconazole. Together, these results suggest that IT-
C is the most potent antiangiogenic and anticancer agent with the least hepatotoxicity 
among the four stereoisomers of itraconazole. 
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3.3 Materials and methods 
Cells 
          HUVECs (Lonza) were grown in endothelial cell growth medium-2 (EGM-2) using 
the EGM-2 bullet kit (Lonza) per manufacturer's instructions. HUVEC phenotype was 
verified by morphological observation throughout serial passage by the manufacturer. 
Human pericytes (placental derived) were purchased from Zen-Bio (Research Triangle 
Park, NC) and were grown in the complete pericyte growth medium (Zen-Bio). 
HCC1954 human breast cancer and CWR22Rv1 human prostate cancer cells were grown 
in RPMI-1640 medium containing 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, 
CA) and 1% antibiotic (penicillin and streptomycin) solution (Invitrogen). The cells were 
maintained in a humidified incubator at 37°C adjusted to 5% CO2. 
 
Reagents 
          Racemic itraconazole and filipin were purchased from Sigma-Aldrich (St Louis, 
MO). Four individual cis-stereoisomers of itraconazole (IT-A, IT-B, IT-C, and IT-D) 
were obtained using preparative supercritical fluid chromatography (SFC) separation 
of commercial itraconazole, which was performed by WuXi AppTec. Quality control of 
each purified stereoisomer was conducted by chiral HPLC and optical rotation using 
previously synthesized stereoisomer samples as standards (27). Low-density lipoprotein 
(LDL) from human plasma was purchased from Fisher Scientific. 
 
HUVEC proliferation assay 
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          HUVEC (5,000 cells/well) were seeded in 96-well plates containing 0.2 mL of 
EGM-2 medium and allowed to adhere at 37°C for 24 hours. The cells were then treated 
with various concentrations of each compound for 24 hours. Cells were pulsed with 
0.5 mCi [3H]-thymidine (PerkinElmer) for 16 hours, before the cells were treated with 1 
× trypsin-EDTA (Invitrogen). The detached cells were harvested onto FilterMat A glass 
fiber filters (Wallac) using a Harvester 96 cell harvester (Tomtec). [3H]-thymidine counts 
were determined using a MicroBeta plate reader (PerkinElmer). Each treatment was done 
in triplicate and the experiments were conducted four times independently. The IC50 
values of each compound and their95%confidence intervals were calculated using the 
GraphPad Prism 5.0 software (GraphPad Software). 
 
Immunobloting 
          Immunobloting assays were performed as described in Chapter 2. 
 
Filipin staining 
          HUVEC were seeded at 3 × 104 cells per well in a Nunc Lab-Tek II Chamber Slide 
(Thermo Fisher Scientific) and allowed to adhere overnight. Following drug treatment for 
24 hours, cells were fixed in 4% paraformaldehyde in PBS (pH 7.4) for 20 minutes and 
then washed with PBS three times. The slides were incubated with PBS containing filipin 
(at a final concentration of 50 mg/mL) in the dark for 1 hour at room temperature. The 
cells were then washed with PBS three times, mounted with Immumount (Thermo Fisher 
Scientific), and stored in the dark before imaging with a Zeiss 510 Meta confocal 
microscope (Carl Zeiss). 
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HUVEC tube formation assay 
          The tube formation assay, a model for assessment of angiogenesis in vitro, was 
conducted as previously described (28). Briefly, a 96-well plate was coated with Matrigel 
(BD Biosciences) by adding 50 mL of ice-cold Matrigel solution per well followed by 
incubation at 37°C for 1 hour. HUVEC were then seeded on the Matrigel-coated wells (2 
× 104 cells/well). Cells were treated with compound alone or in combination with LDL 
and then incubated in a CO2 incubator for 16 hours. For the posttreatment experiments, 
compounds were added to the cells 6 hours after seeding on Matrigel and the incubation 
was continued for 18 hours. The cells were washed carefully with PBS once, and 
Calcein-AM (BD Biosciences) solution in PBS (2 mmol/L final concentration) was 
added. After incubation at 37°C for an additional 30 minutes, the cells were washed with 
PBS and the fluorescence-labeled HUVEC tubes were observed under the Nikon Eclipse 
TS100 fluorescence microscope (485-nm excitation and 520-nm emission) at 
magnification ×100. Each treatment was done in triplicate and the experiments were 
conducted three times independently. The total tube length, size, and number of junctions 
from the fluorescence images were quantified using the AngioQuant v1.33 software (The 
MathWorks). 
 
HUVEC-pericyte co-culture tube formation 
          Growing pericytes in a 6-cm cell culture dish were labeled with Calcein-AM for 30 
minutes before the tube formation experiments. Ibidi m-Slide angiogenesis chamber 
(Ibidi) was coated with Matrigel by adding 10 mL of ice-cold Matrigel solution per well 
followed by incubation at 37°C for 1 hour. HUVEC (1.5 × 104 cells/well) and pericytes 
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(500 cells/well) were mixed at a ratio of 30:1 in complete EGM-2 media, seeded on the 
Matrigel-coated wells and then treated with compounds. After 20 hours of incubation, the 
co-culture tube formation was analyzed under a Zeiss AxioObserver Z1 fluorescence 
microscope with ApoTome apparatus (Carl Zeiss) at magnification ×50. The total tube 
lengths of the fluorescence-labeled pericytes were quantified using the AngioQuant v1.33 
software. 
 
Determination of hepatotoxicity in primary human hepatocytes 
          Fresh primary human hepatocytes (6-well plates) with Matrigel overlay from three 
donors were obtained from XenoTech, LLC. Ages and genders of donors were as 
follows: 22-year-old male, 54-year-old male, and 63-year-old male. Hepatocyte viability 
from each donor was at least 74%. Upon receipt of the hepatocytes, the shipping medium 
was replaced with Williams' Medium E supplemented with 10% FBS (Invitrogen), 
penicillin–streptomycin (Sigma-Aldrich), and L-glutamine (Invitrogen). The hepatocytes 
were then incubated overnight at 37°C in a 5% CO2 humidified environment. Following 
the overnight incubation the medium was replaced with fresh William's Medium E 
supplemented as described above and the hepatocytes were incubated with DMSO 
(vehicle control, 0.1% final volume), racemic itraconazole (2 mmol/L or 10 mmol/L) as 
well as stereoisomers denoted as IT-A, IT-B, IT-C, and IT-D at a final concentration of 
either 2 or 10 mmol/L for 72 hours. Following incubation, to monitor hepatocyte 
function, the medium was removed and alanine aminotransaminase (ALT) levels were 
measured using an alanine aminotransaminase activity assay kit purchased from 
BioVision Inc. Cell viability following treatment with itraconazole and stereoisomers was 
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determined using the Cell Death Detection ELISA Kit according to the manufacturer's 
instructions (Roche Diagnostics Corporation) as we have reported previously (29). 
Intracellular glutathione (GSH) was measured using HPLC by quantification of the 5-
thio-2-nitrobenzoic acid formed following the addition of Ellman's reagent to hepatocyte 
lysates as previously described (30). 
 
Determination of hepatotoxicity in mice 
          Female mice (BALB/c, AnNCr) ages 6 to 8 weeks were purchased from the 
National Cancer Institute (Frederick, MD) and treated in accordance with Johns Hopkins 
Animal Care and Use Committee procedures. Mice (n = 5/group) were treated 
intraperitoneally (i.p.) with vehicle (saline with 5% DMSO, 5% PEG500, and 5% tween-
80), 60 mg/kg itraconazole, 60 mg/kg IT-A, and 60 mg/kg IT-C once daily for 10 days. 
Mice were sacrificed and livers from each group were isolated, photographed, and fixed 
in 10% neutral- buffered formalin (Sigma-Aldrich). Fixed liver tissues were embedded in 
paraffin, processed for histology sections and stained with hematoxylin and eosin (H&E). 
 
In vivo Matrigel plug angiogenesis assay 
          Female mice (BALB/c, AnNCr) ages 6 to 8 weeks were used for the Matrigel plug 
angiogenesis assay. Mice (n = 5/group) were pretreated i.p. with vehicle (saline with 5% 
DMSO, 5% PEG500, and 5% tween-80), itraconazole (20 and 50 mg/kg), IT-A (20 and 
50 mg/kg), and IT-C (20 and 50 mg/kg) once daily for 2 days before Matrigel 
implantation. Matrigel (0.5 mL/injection) containing 200 ng/mL VEGF and 500 ng/mL 
basic fibroblast growth factor (bFGF) was implanted subcutaneously into mice. The drug 
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treatment was continued once daily for an additional 8 days. Mice were sacrificed and 
whole Matrigel plugs with mouse skin were excised, fixed in 10% neutral-buffered 
formalin, embedded in paraffin. For staining infiltrated cells in the Matrigel, the fixed 
Matrigel plugs were processed for histochemical staining using Masson trichrome 
staining, which stains the Matrigel blue and the infiltrated cells and vessels red. 
For staining functional vasculatures, the fixed Matrigel plugs were stained with anti-
CD31 (BD Pharmingen), a blood vessel marker, and anti-NG2 (Abcam), a pericyte 
marker, to assess Matrigel plug angiogenesis. A cross-section of the Matrigel plug was 
photographed at ×100 magnification under a Nikon Eclipse TS100 microscope and 
CD31-positive blood vessels and NG2-stained cells were counted per field for 
quantification of angiogenesis. 
 
In vivo tumor xenograft assay 
          Female athymic nude mice (BALB/c, nu/nu-NCr) ages 6 to 8 weeks were 
purchased from the National Cancer Institute (NCI)-Frederick and treated in accordance 
with Johns Hopkins AnimalCare and Use Committee procedures. HCC1954 human 
breastcancer cells (2 × 106) were implanted subcutaneously into the mice. After tumors 
became palpable, the mice (n = 7/group) were treated i.p. with vehicle (saline with 5% 
DMSO, 5% PEG500, and 5% tween-80), itraconazole (25 and 50 mg/kg), and IT-C (25 
and 50 mg/kg) once daily for 30 days. For CWR22Rv1 human prostate cancer 
xenografts, male athymic nude mice (BALB/c, nu/nu-NCr) ages 6 to 8 weeks (NCI-
Frederick) were used for tumor cell implantation (2 × 106 cells/injection). The tumor-
bearing mice (n = 6/group) were treated i.p. with vehicle, itraconazole (20 and 60 mg/kg) 
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and IT-C (20 and 60 mg/kg) once daily for 24 days. The tumor volume was measured 
periodically using a vernier caliper and calculated according to the modified ellipsoid 
formula: tumor volume (mm3) = (width)2 × (length) × π/6. After treatment, the mice were 
sacrificed and whole tumor tissues from the HCC1954 xenograft were excised. Tumor 
tissues were then fixed in 10% neutral-buffered formalin, embedded in paraffin and 
sliced to obtain 5-mm sections. The blood vessels in the tumor tissue sections were 
stained with an anti-CD31 antibody (BD Pharmingen), a blood vessel marker, to assess 
tumor angiogenesis angiogenesis. A cross-section of the tumor tissue was photographed 
at magnification ×100 under the Nikon Eclipse TS100 microscope and blood vessels 
stained with anti-CD31 antibody were counted per field for the quantification of tumor 
angiogenesis. The lumen sizes of the blood vessels were also quantified using the Zen 
image analysis tool (Carl Zeiss). 
 
Statistical analysis 
          Statistical analysis of the data was performed using Graph-Pad Prism version 5.0. 
Statistical significance, determined by the two-tailed Student t test (between two groups) 
and twotailed single sample t test (test group vs. hypothetical control value), is indicated 
throughout by the following: *, P ≤ 0.05 
and **, P ≤ 0.01. 
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3.4 Results 
Racemic itraconazole and its stereoisomers inhibited HUVEC proliferation with 
different potencies 
          Racemic itraconazole and each of the four purified cis-stereoisomers were tested 
for HUVEC proliferation by measuring the ability of the cells to incorporate [3H]-
thymidine into DNA. Itraconazole dose-dependently inhibited the thymidine 
incorporation of HUVEC with an IC50 value of 137 nmol/L (Table 3.1). Under the same 
assay conditions, the 2S4R stereoisomers, including IT-A and IT-C, showed more potent 
inhibition against HUVEC proliferation compared with itraconazole with IC50 values of 
103 and 98 nmol/L, respectively. However, the 2R4S stereoisomers including IT-B and 
IT-D were less potent than itraconazole with IC50 values of 223 and 199 nmol/L, 
respectively. Collectively, 2S4R stereoisomers were roughly two times more potent than 
2R4S stereoisomers in HUVEC proliferation. A one-to-one combination of IT-A and IT-
C or IT-B and IT-D showed no synergy in HUVEC proliferation, suggesting that they 
might share the same mechanism of action to inhibit HUVEC proliferation (Table 3.1). 
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Table 3.1 Chemical structures of itraconazole cis-stereoisomers and their 




Mean IC50 values and their 95% confidence intervals (CI) from 4 independent 
experiments are shown. *Inhibitory index represents the ratio of IC50 of stereoisomers or 














Itraconazole Racemic 137.8 127.6 to 148.9 1 - 
IT-A 2S4R2'R 103.6 91.3 to 117.5 0.75 0.042 
IT-B 2R4S2’R 223.1 199.4 to 249.6 1.62 0.001 
IT-C 2S4R2’S 98.3 86.8 to 111.4 0.71 0.003 
IT-D 2R4S2’S 199.5 182.6 to 218.0 1.45 0.005 
IT-A + IT-C 
(1:1)  101.2 91.4 to 112.0  0.73 0.013 
IT-B + IT-D 
(1:1)  211.0 187.4 to 237.5 1.53 0.009 
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Itraconazole stereoisomers inhibited VEGFR2 glycosylation, mTOR activity, and 
cholesterol trafficking in HUVEC 
        We next determined whether all stereoisomers still share a common mechanism of 
action to inhibit endothelial cell proliferation by assessing three previously identified 
activities of itraconazole, that is, inhibition of VEGFR2 glycosylation, mTOR, and 
cholesterol trafficking (NPC phenotype). Itraconazole inhibited VEGFR2 glycosylation 
in HUVEC as evidenced by the dose-dependent shift of high-molecular weight, 
hyperglycosylated form of VEGFR2 to the low-molecular weight, hypo-glycosylated 
form. All four stereoisomers inhibited VEGFR2 glycosylation with slight different 
potencies. All four stereoisomers as well as racemic itraconazole dose-dependently 
inhibited mTOR activity as measured by S6 kinase (S6K) phosphorylation, a downstream 
target of mTOR. It was apparent that IT-A and IT-C (2S4R series) were more potent than 
IT-B and IT-D (2R4S series) for the inhibition of VEGFR2 glycosylation and mTOR 
activity (Figure 3.1 a).  
          Next, we determined the effects of itraconazole and the stereoisomers on 
cholesterol trafficking in HUVEC. Cellular cholesterol was fluorescently labeled by 
filipin and the cholesterol distribution was observed under a confocal microscope. 
HUVEC were treated with either vehicle (DMSO) or 50 nmol/L of itraconazole or 
stereoisomers. The concentration of 50 nmol/L that we used here was the lowest 
concentration of itraconazole that is sufficient to induce an NPC phenotype. At this 
concentration, IT-A and IT-C as well as itraconazole showed an NPC phenotype as 
judged by the accumulation of cholesterol fluorescence in the perinuclear region of 
HUVEC. However, IT-B and IT-D failed to show NPC phenotype at this concentration 
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(Figure 3.1 b). Thus, for inhibition of cholesterol trafficking, mTOR activity and 
VEGFR2 glycosylation, 2S4R series were more potent than 2R4S series, which 




Figure 3.1: Itraconazole and stereoisomers inhibit VEGFR2 glycosylation, mTOR 
activity and cholesterol trafficking.  
(a) HUVEC were treated with itraconazole (ITRA) and its stereoisomers at various 
concentrations (0, 0.125, 0.25, 0.5, and 1 mmol/L) for 24 hours. Whole-cell lysates were 
subjected to western blot analysis using antibodies specific for VEGFR2, phospho-S6K 
(pS6K), and total S6K. In the VEGFR2 Western blots, the top and the bottom bands 
correspond to hyperglycosylated and hypoglycosylated forms, respectively. (b) HUVEC 
were treated with 50 nmol/L of itraconazole and stereoisomers for 24 hours. The cells 
were stained with filipin and the fluorescent images were captured under a confocal 
microscope.  
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Inhibition of angiogenesis by itraconazole stereoisomers is dependent on cholesterol 
          We next used an in vitro tube formation assay to assess the activity of the 
stereoisomers. Upon seeding on top of solidified Matrigel, individual endothelial cells 
migrate and elongate to form tubule-like networks, reminiscent of new blood vessel 
formation. Treatment of HUVEC with 3 mmol/L itraconazole, IT-A and IT-C strongly 
inhibited HUVEC tube formation (Figure 3.2). However, treatment with IT-B and IT-D 
showed little or no inhibition of HUVEC tube formation at the same concentration 
(Figure 3.2), again demonstrating that IT-A and IT-C are more potent than the other two 
stereoisomers.  
          To see whether the compounds are able to inhibit pre-formed tubes of HUVEC, 
itraconazole and stereoisomers were added 6 hours after cell seeding on Matrigel and the 
incubation was continued for an additional 18 hours. At a higher concentration (6 
mmol/L), itraconazole and the two potent stereoisomers (IT-A and IT-C) significantly 
inhibited the pre-formed tubes of HUVEC, again verifying that IT-A and IT-C are more 
potent anti angiogenic agents than IT-B and IT-D (Figure 3.3).  
          As the antiproliferative activity of itraconazole was shown to be dependent on 
cholesterol trafficking (20), we conducted a rescue experiment of angiogenesis inhibition 
by itraconazole and stereoisomers with LDL. Treatment of HUVEC with LDL slightly 
enhanced the tube formation of HUVEC. When HUVEC was treated with itraconazole or 
stereoisomers together with LDL, the inhibition of tube formation formation was 
completely reversed to the control level (Figure 3.4 a and b). Furthermore, inhibition of 
VEGFR2 glycosylation by itraconazole or stereoisomers was also completely reversed by 
LDL (Figure 3.4 c and d). These results indicated that, similar to itraconazole, the 
antiangiogenic activity of the different stereoisomers is dependent on their ability to 
inhibit cholesterol trafficking. 
 
Figure 3.2: Effect of itraconazole and its stereoisomers on HUVEC tube formation.  
(a) HUVEC were seeded on Matrigel and treated with itraconazole and stereoisomers at 
the concentration of 3 µmol/L for 16 hours. Cells were then stained with Calcein-AM and 
the tube formation was observed under a fluorescent microscope. (b) Total tube length, 
size and number of junctions from the fluorescence images were quantified using the 
AngioQuant software and plotted using the Graphpad prism. Data represent the mean ± 
SE of three independent experiments. *, P ≤ 0.05 for the drug versus DMSO control 
(two-tailed Single Sample t-test).  
Figure 3.3: Effect of itraconazole and its stereoisomers on pre-formed HUVEC tube 
formation.  
(a) HUVEC were seeded on Matrigel and allowed for tube formation for 6 hours. The 
pre-formed tubes were then treated with itraconazole and stereoisomers at the 
concentration of 3 and 6 µmol/L and incubated for additional 18 hours. Cells were then 
stained with Calcein-AM and the tube formation was observed under a fluorescent 
microscope. (b) Average tube length, size and number of junctions from the fluorescence 
images were quantified using the AngioQuant software and plotted using the Graphpad 
prism. Data represent the mean ± SE of three independent experiments. *, P ≤ 0.05 for 
the drug versus DMSO control (two-tailed Single Sample t-test).  
Figure 3.4: LDL rescued angiogenesis inhibition by itraconazole and stereoisomers.  
(a) HUVEC were seeded on Matrigel and treated with itraconazole and stereoisomers at 
the concentration of 3 mmol/L and LDL (50 mg/mL) for 16 hours. Cells were then 
stained with Calcein-AM and the tube formation was observed under a fluorescent 
microscope. (b) Total tube lengths, sizes and number of junctions from the fluorescence 
images were quantified using the AngioQuant software and plotted using GraphPad 
Prism. Data, mean ± SE of three independent experiments. **, P ≤ 0.01 for drug alone 
versus drug + LDL. (c) and (d), HUVEC were treated with indicated concentrations of 
itraconazole and stereoisomers with or without LDL (50 mg/mL) for 24 hours. Western 
blot analysis was done using antibodies specific for VEGFR2 and GAPDH as a loading 
control. 
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Racemic itraconazole and its stereoisomers inhibited HUVEC-pericyte co-culture 
tube formation 
          Pericytes are vascular-supporting cells that interact with endothelial cells and play 
an important role in initiation of angiogenesis by guiding the endothelial cell sprouting 
and stabilizing the vessels (31). Therefore, pericytes, together with endothelial cells, have 
been recognized as a putative target in cancer treatment (32). To examine the effects of 
racemic itraconazole and its stereoisomers on pericyte angiogenesis, we performed 
pericyte alone and pericyte-HUVEC co-culture tube formation experiments. Under our 
experimental conditions, and as shown in other reports, pericytes alone could not form 
tubular networks on Matrigel. We therefore used HUVEC-pericyte co-culture tube 
formation at a ratio of 30:1 of HUVEC and pericytes, respectively. At a concentration of 
3 mmol/L, racemic itraconazole, IT-A and IT-C significantly inhibited pericyte tube 
networks as well as overall co-culture tube formation on Matrigel (Figure 3.5). In 
contrast, IT-B and IT-D showed negligible effects on co-culture tube formation. These 
results indicated that racemic itraconazole and the two stereoisomers IT-A and IT-C 
inhibited angiogenesis in the presence of pericytes. 
  
Figure 3.5: Itraconazole and stereoisomers inhibit the tube formation of HUVEC-
pericyte co-culture.  
(a) Pericytes were labeled with Calcein-AM for 30 minutes before being harvested for 
tube formation. HUVEC and pericyte mixture (30:1 ratio) were treated with compounds 
at 3 mmol/L, seeded on Matrigel and allowed to form tube networks for 20 hours. Total 
cells (HUVEC and pericytes) are shown in the brightfield images and pericytes are 
shown in the green fluorescent images; scale bar, 200 μm. (b) total tube length from the 
green fluorescence images were quantified as the pericyte tube formation using the 
AngioQuant software and plotted using Graphpad Prism. Data, mean ± SE of three 
independent experiments. *, P ≤ 0.05; **, P ≤ 0.01 for control versus drug. 
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Itraconazole stereoisomers possess distinct hepatotoxicity profiles 
          Having shown that the 2S4R pair of itraconazole stereoisomers are more potent 
than 2R4S pair in all in vitro angiogenesis-related assays, we wondered whether the 
stereochemistry had a similar influence on the relative hepatotoxicity of the different 
stereoisomers. Using freshly prepared human primary hepatocytes, we determined three 
representative markers of hepatotoxicity, including hepatocyte death, intracellular GSH 
depletion, and alanine transaminase (ALT) release. As expected, incubation with 2 and 
10 mmol/L itraconazole increased primary human hepatocyte death 1.6- and 1.8-fold 
(P ≤ 0. 1), respectively, as compared with vehicle control (Figure 3.6 a). Similarly, 
itraconazole effects on GSH depletion (76%; P ≤ 0.01) and ALT levels in the cell culture 
medium (92.5 IU/L; P ≤ 0.01) were consistent with the hepatotoxicity (Figure 3.6 b and 
c). Interestingly, IT-A and IT-B (both have a 2’ R stereochemistry) appeared to have 
slightly higher hepatotoxicity than racemic itraconazole as judged by induction of cell 
death by 2.2- (P ≤ 0.01) and 2.0-fold (P ≤ 0.01), respectively, at a final concentration of 
10 mmol/L as well as increases in GSH depletion [70% (P ≤ 0.01) and 67% (P ≤ 0.01), 
respectively] and extracellular ALT levels [117 IU/L (P ≤ 0.01) and 128 IU/L (P ≤ 0.01), 
respectively]. In contrast, ITC and IT-D (both have a 2’S stereochemistry) did not show 
appreciable hepatotoxicity, as judged by cell death, hepatic GSH levels or the 
concentration of ALT in the culture medium (Figure 3.6 a-c). These results were quite 
unexpected as the hepatotoxicity profile is totally different from the antiangiogenic 
profile of stereoisomers. Thus, the stereochemistry at the C2 and C4 chiral centers of 
itraconazole appeared to be important for the antiangiogenic activity whereas that of the 
C2’ chiral center influences hepatotoxicity. 
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          We next assessed the hepatotoxicity of the stereoisomers in mice. Female mice 
were administered with vehicle or itraconazole stereoisomers (60 mg/kg) i.p. once daily 
for 10 days. After drug treatment, we first determined the ALT levels in the blood 
samples of the mice, but found no significant change in blood ALT levels from the mice 
treated with stereoisomers (data not shown). Next, livers from each mouse were isolated 
and processed for H&E staining. The livers from vehicle or IT-C–treated mice appeared 
normal, whereas those from IT-A–treated mice showed abnormalities, that is, white 
colored and quite sticky to surrounding tissues. In comparison, livers in mice treated with 
itraconazole looked partially abnormal (data not shown). From the H&E staining of the 
liver sections, we found that IT-A caused severe fatty liver in the mice (Figure 3.7). Mice 
treated with racemic itraconazole had partial fatty liver, whereas livers from those treated 
with vehicle or IT-C were normal (Figure 3.7). Once again, IT-C showed less 
hepatotoxicity in mice than either IT-A or the racemic itraconazole, consistent with the 
results from human hepatocytes. 
  
Figure 3.6: Itraconazole and each stereoisomer have distinct hepatotoxicity profiles.  
(a) to (c) Freshly prepared human primary hepatocyteswere incubated with itraconazole 
and stereoisomers at the indicated concentrations for 72 hours. Cell viability of the 
hepatocytes (a), intracellular glutathione levels from the hepatocyte lysates (b), and the 
alanine aminotransaminase (ALT) levels from the hepatocyte culture media (c) were 
measured as described in the Materials and Methods. *, P ≤ 0.05; **, P ≤ 0.01 for 10 
mmol/L versus 0 mmol/L (for a and b, two-tailed single sample t test). **, P ≤ 0.01 for 
drug versus DMSO control (for c, two-tailed Student t test). 
 
 
Figure 3.7: Itraconazole and each stereoisomer have distinct hepatotoxicity.  
Female BALB/cAnNCr mice were treated i.p. with itraconazole and stereoisomers at the 
dosage of 60 mg/kg for 10 days. Livers from each mouse were isolated and processed for 
H&E staining. Representative images from five mice per group are shown; scale bar, 100 
μm. 
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IT-C inhibited angiogenesis in vivo 
          We next determined and compared the in vivo antiangiogenic activity of IT-A and 
IT-C along with racemic itraconazole as a control. We excluded the 2R4S series (IT-B 
and IT-D) from these experiments because they had lower antiangiogenic activity than 
2S4R series. Female mice were pre-treated with IT-A, ITC, or itraconazole at the doses 
of 20 and 50 mg/kg for each compound for 2 days. The mice were then implanted 
subcutaneously with Matrigel plugs containing angiogenic factors, including bFGF and 
VEGF. Treatment with vehicle or compounds was continued once daily for additional 8 
days. Mice were sacrificed and Matrigel plugs were isolated from the mice for the 
immunohistologic analysis of blood vessel infiltration into the Matrigel using anti-CD31 
(endothelial cell marker) and anti-NG2 (pericyte marker) antibodies. In addition to the 
antibody staining, entire population of cells infiltrated into the Matrigel plugs was 
analyzed using Masson's trichrome staining (Figure 3.8). Compared with the vehicle 
control, itraconazole inhibited the number of CD31-positive blood vessels infiltrated into 
the Matrigel by 19% and 46% at the dosage of 20 and 50mg/kg, respectively (Figure 3.9 
a and b). IT-A also inhibited the CD31-positive blood vessels by 19% and 48%. IT-C 
showed more significant inhibition on CD31-positive Matrigel angiogenesis, with 
41%and 60% inhibition at 20 and 50 mg/kg, respectively (Figure 3.9 a and b). Similar 
results were observed in NG2-positive pericyte staining. IT-C exhibited the strongest 
inhibition on the infiltration and vessel formation by NG2-positive pericytes, with 47% 
and 70% inhibition at 20 and 50 mg/kg, respectively (Figure 3.9 c and d). These results 
suggested that IT-C is more active than IT-A for the antiangiogenic activity. 
  
Figure 3.8: Effect of itraconazole and the 2S4R series of stereoisomers on in vivo 
Matrigel angiogenesis in mice.  
(a) Female BALB/cAnNCr mice with Matrigel implantation were treated i.p. with 
itraconazole, IT-A and IT-C at dosages of 20 and 50 mg/kg for total of 10 days (2-day 
pre-treatment and 8-day post-treatment of Matrigel implantation). Matrigel plugs with 
mouse inner skin were isolated and processed for Masson trichrome staining which stains 
Matrigel blue and the endothelial cells and vessels red. Representative Matrigel images 
from 5 mice per group are shown. Arrows indicate mouse inner skin (a layer of dark blue 
color) where blood vessels begin to penetrate into the Matrigel. (b) The number of 
erythrocyte-containing blood vessels were counted from photos taken under a bright-field 
microscope and plotted using Graphpad Prism. Data represent mean ± SE of four 
independent Matrigel images per group. *, P ≤ 0.05; **, P ≤ 0.01 for each drug versus 
vehicle control. 
 
Figure 3.9: Itraconazole and the 2S4R series of stereoisomers inhibit Matrigel 
angiogenesis in vivo.  
(a) and (c) Female BALB/cAnNCr mice with Matrigel implantationwere treated i.p. with 
itraconazole, IT-A and IT-C at dosages of 20 and 50 mg/kg for total of 10 days (2-day 
pre-treatment and 8-day post-treatment of Matrigel implantation). Matrigel plugs with 
mouse inner skin were isolated and processed for immunohistochemical (IHC) staining of 
CD31 (endothelial cell marker) and NG2 
(pericyte marker). Representative IHC images of CD31 staining (a) and NG2 staining (c) 
are shown. (b) and (d) The number of CD31-positive vessels (b) and NG2-positive cells 
(d) were counted from the IHC samples and plotted using Graphpad Prism. Data, mean ± 
SE of three independent IHC samples per group. *, P ≤ 0.05; **, P ≤ 0.01 for each drug 
versus vehicle control; scale bar, 1.79 mm. 
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  IT-C inhibited tumor growth and tumor-induced angiogenesis in mice 
          Taking into consideration both the antiangiogenic activity and hepatotoxicity, IT-C 
was deemed superior to all other stereoisomers due to a combination of its higher 
antiangiogenic potency and lack of hepatotoxicity in both human cells and mice. We thus 
assessed the antitumor activity of IT-C in two tumor xenograft models (breast cancer and 
prostate cancer) in parallel with racemic itraconazole. We also took the opportunity to 
determine the effect of IT-C on tumor-induced angiogenesis. For the breast cancer 
xenograft model, female athymic nude mice bearing HCC1954 cells were treated i.p. 
with vehicle, itraconazole, or IT-C at 25 and 50 mg/kg for each compound, once daily, 
for 30 days. Racemic itraconazole at 50 mg/kg significantly inhibited the growth of 
HCC1954 xenografts compared with the vehicle alone (Figure 3.10 a). Tumor volume 
was reduced by 40% at day 28 of treatment with 50 mg/kg itraconazole compared with 
the vehicle control. Importantly, IT-C showed more pronounced inhibition of the tumor 
xenograft growth than itraconazole at both 25 and 50 mg/kg (Figure 3.10 b). It inhibited 
the tumor volume by 53% at day 28 at 50 mg/kg. There were no apparent toxicities 
associated with itraconazole or IT-C based on assessment of mouse body weight 
(Figure 3.10 c). Similar results were observed in the CWR22Rv1 prostate cancer 
xenograft model. Treatment of male athymic nude mice with either itraconazole (60 
mg/kg) or IT-C (60 mg/kg) significantly inhibited the tumor growth (Figure 3.10 d and 
e). To assess tumor-associated angiogenesis in the breast cancer xenografts, the tumor 
tissues were harvested from the mice and processed for immunohistochemical analysis of 
CD31, a blood vessel marker. Compared with the vehicle, both racemic itraconazole and 
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IT-C significantly inhibited angiogenesis in the HCC1954 xenografts (Figure 3.11), with 
IT-C being more potent than itraconazole. 
  
 
Figure 3.10: Itraconazole and IT-C inhibit the tumor growth in vivo.  
(a) and (b) Female athymic nude mice (BALB/c, nu/nu-NCr) bearing HCC1954 human 
breast cancer cells were treated with itraconazole (ITRA, a) or IT-C (b) for 30 days. (c) 
Female athymic nude mice bearing breast cancer xenograft were given indicated drugs 
daily for 30 days and the body weight was measured periodically. (d) and (e) Male 
athymic nude mice (BALB/c, nu/nu-NCr) bearing CWR22Rv1 human prostate cancer 
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cells were treated with itraconazole (ITRA, d) or IT-C (e) for 24 days. Tumor volume 
was measured periodically by a vernier caliper and plotted using GraphPad prism. Data, 
mean ± SE of tumor volumes in each group (n = 6-7mice). *, P ≤ 0.05; **, P ≤ 0.01 for 
the drug versus vehicle control at each time point. 
  
 
Figure 3.11: Itraconazole and IT-C inhibit the angiogenesis in vivo.  
(a) HCC1954 tumor xenograft tissues were processed for immunohistochemical (IHC) 
staining of a blood vessel marker, CD31. Representative images of CD31 staining of 
tumor sections from each group are shown; scale bar, 100 mm. (b) The number of CD31-
positive blood vessels were counted from photos taken under a bright-field microscope 
and plotted using GraphPad Prism. The lumen size of blood vessels were measured using 
the Zen image analysis tool. Data, mean ± SE of the number and the lumen size of blood 
vessels from the IHC images (n = 5/group). **, P ≤ 0.01 for each drug versus vehicle 
control. 
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3.5 Discussion 
          Although itraconazole has been widely used to treat fungal infections, several 
adverse effects have been reported. The most frequent side effects associated with 
itraconazole are gastrointestinal complaints including nausea, vomiting, diarrhea, 
flatulence and constipation (33). Fortunately, these adverse effects are mostly transient 
and mild, and thus are tolerable to patients (34). However, rare but severe hepatoxicity 
associated with itraconazole has also been reported. Up to 7% of patients receiving 
itraconazole have elevated ALT levels (22). Moreover, fatalities due to hepatic failure 
have been reported in patients receiving itraconazole (35). Major efforts have been made 
to overcome the adverse effects of itraconazole on the liver. A pulse therapy of 
itraconazole (typically, 400mgitraconazole twice daily for 1 week followed by a three-
weeks holiday) was introduced in superficial fungal infections based on the 
pharmacokinetic (PK) properties of itraconazole (36). Upon cessation of drug intake, 
itraconazole is rapidly cleared from systemic circulation (7–10 days), but persists for 3 to 
4 weeks in the stratum corneum and for up to 6 to 12 months in the nail (37). This PK 
property of itraconazole makes pulse therapy for onychomycosis and dermatomycoses 
possible, which could significantly reduce the hepatotoxicityrelated adverse effects while 
showing therapeutic efficacies similar to continuous therapy (38). However, this strategy 
may not be applicable for the cancer therapy, which requires a high dose of itraconazole 
in systemic circulation. Thus, the hepatotoxicity associated with itraconazole still poses a 
significant challenge for the long-term, high-dose treatment of cancer patients with 
itraconazole.  
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          Hepatotoxicity associated with itraconazole has long been recognized, but the 
mechanism underlying the liver toxicity of itraconazole has remained obscure. 
Cytochrome P450, specifically CYP3A4, is a main liver enzyme responsible for the 
metabolism of itraconazole (39). Itraconazole also inhibits the enzyme activity of 
CYP3A4 (24). When rats were pretreated with phenobarbital, an inducer of cytochrome 
P450, hepatotoxicity induced by itraconazole was significantly reduced (25, 34). On the 
other hand, pretreatment of rats with SKF 525A, an inhibitor of cytochrome P450, 
significantly enhanced itraconazole-induced hepatoxicity (25). These results suggest that 
inhibition of cytochrome P450, probably CYP3A4, by itraconazole is, at least in part, 
responsible for itraconazoleinduced hepatotoxicity. Commercial itraconazole currently 
used in the clinic is a racemic mixture of four cis-stereoisomers. It is interesting to note 
that CYP3A4 metabolizes itraconazole in a stereoselective manner. Only IT-B and IT-D 
are metabolized by CYP3A4 among the four stereoisomers. Although all four 
stereoisomers are strong binders and inhibitors of CYP3A4, IT-B, and IT-D have 2- to 4-
fold stronger binding affinity for CYP3A4 and 2- to 4-fold lower IC50 values for 
inhibition of the enzymatic activity of CYP3A4 in comparison with IT-A and IT-C (26). 
In the present study, we confirmed that IT-A and IT-C were more potent inhibitors of 
angiogenesis than IT-B and IT-D. In contrast, IT-A and IT-B were much more 
hepatotoxic than IT-C and IT-D both in mice and in human hepatocytes. These results 
suggest that inhibition of CYP3A4 by itraconazole or metabolism of itraconazole by 
CYP3A4 may not be solely responsible for its hepatotoxicity. One interesting possibility 
is that a cytochrome P450 enzyme with specificity for the C20 chiral center of 
itraconazole could be the main enzyme mediating the hepatotoxicity of itraconazole. In 
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addition, the segregation of antiangiogenic activity and hepatotoxicity of the four 
stereoisomers of itraconazole suggests that the cellular target protein(s) responsible for 
angiogenesis inhibition and hepatotoxicity might be different. Answers to these questions 
may become clear upon identification of the molecular targets mediating the different 
effects of itraconazole. 
          Although itraconazole was shown to elevate serum ALT levels in rats, it did not 
increase the levels in mice in this study. Instead, itraconazole and IT-A induced moderate 
to severe fatty liver in mice. Rats and mice have shown different hepatotoxicity responses 
to certain compounds, such as coumarin (40). Interstrain differences of hepatotoxicity 
responses have also been observed in mice treated with cocaine and phenobarbital (41). 
This is thought to be due to the different liver metabolic enzymes present in different 
strains and animal species. Itraconazole has shown similar hepatotoxicity profiles in 
humans and rats, suggesting that they respond similarly to this compound. In mice, the 
compound did not show ALT elevation, but induced fatty liver, suggesting that racemic 
itraconazole and IT-A still have negative impact on mice liver but in a way different from 
rats or humans. However, IT-C at doses up to 60 mg/kg did not cause apparent adverse 
effects on the mouse liver. In the experiments using human primary hepatocytes, ITC 
showed no apparent signs of hepatotoxicity at concentrations up to 10 mmol/L for all 
three hepatotoxicity markers. In contrast, IT-A was strongly hepatotoxic and racemic 
itraconazole showed a medium degree of hepatotoxicity. Together, these results points to 
IT-C as the most promising candidate for future clinical development with improved 
potency and decreased hepatotoxicity in comparison with racemic itraconazole. 
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That the C20 stereochemistry has a major influence on the hepatotoxicity of itraconazole 
should also facilitate the development of next generations of itraconazole analogs as new 
leads of antiangiogenic and anticancer drugs. 
          Several antiangiogenic agents, such as sunitinib and sorafenib, have successfully 
entered into the clinic as targeted cancer therapies. Although these agents have 
dramatically changed the management of cancer in patients these days, many clinical 
challenges still remain, including the huge financial burden to patients and the emergence 
of drug resistance that occurs with most of the kinase inhibitor drugs. Development of 
new antiangiogenic and anticancer agents from existing non-cancer drugs (the drug 
repositioning strategy) offers the possibility of reducing the financial burden to patients 
(42). In addition, this approach can also diversify molecular targets as exemplified with 
itraconazole, which is not a kinase inhibitor. Development of agents with diverse 
molecular targets provides better opportunities to find drug combinations with standard 
chemotherapy or current targeted drugs to reduce the emergence of cancer drug 
resistance. As evidenced from recent clinical investigations, itraconazole has shown 
positive clinical outcome in patients with non–small cell lung cancer, metastatic prostate 
cancer, and basal cell carcinoma. It also showed prolonged survival in patients with late-
stage ovarian, triple-negative breast, and metastatic pancreatic cancer. IT-C, as an 
equipotent isomer of itraconazole with reduced hepatotoxicity, will have a wider range of 
therapeutic window than racemic itraconazole, and thus is a promising lead for future 
development as an antiangiogenic and anticancer drug.  
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Chapter 4: Inhibition of angiogenesis by selective estrogen 
receptor modulators through blockade of cholesterol 
trafficking rather than estrogenreceptor antagonism 
4.1 Abstract 
          In Chapter 3, I described a pharmacological study of the itraconazole and its 
stereoisomers to distinguish their differences in anti-angiogenesis effect and 
hepatotoxicity. As I mentioned in above chapter, itraconazole and its stereosiomers block 
membrane and cholesterol trafficking and inhibit angiogenesis and tumor growth.  In this 
chapter, I will describe another pharmacological study to demonstrate the inhibition of 
angiogenesis by selective estrogen receptor modulators, such as tamoxifen, through 
blockade of cholesterol trafficking rather than estrogen receptor antagonism. Selective 
estrogen receptor modulators (SERM) including tamoxifen are known to inhibit 
angiogenesis. However, the underlying mechanism, which is independent of their action 
on the estrogen receptor (ER), has remained largely unknown. In the present study, we 
found that tamoxifen and other SERM inhibited cholesterol trafficking in endothelial 
cells, causing a hyper-accumulation of cholesterol in late endosomes/lysosomes. 
Inhibition of cholesterol trafficking by tamoxifen was accompanied by abnormal 
subcellular distribution of vascular endothelial growth factor receptor-2 (VEGFR2) and 
inhibition of the terminal glycosylation of the receptor. Tamoxifen also caused 
perinuclear positioning of lysosomes, which in turn trapped the mammalian target of 
rapamycin (mTOR) in the perinuclear region of endothelial cells. Abnormal distribution 
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of VEGFR2 and mTOR and inhibition of VEGFR2 and mTOR activities by tamoxifen 
were significantly reversed by addition of cholesterol cyclodextrin complex to the culture 
media of endothelial cells. Moreover, high concentrations of tamoxifen inhibited 
endothelial and breast cancer cell proliferation in a cholesterol-dependent, but ER-
independent, manner. Together, these results unraveled a previously unrecognized 
mechanism of angiogenesis inhibition by tamoxifen and other SERM, implicating 
cholesterol trafficking as an attractive therapeutic target for cancer treatment. 
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ABBREVIATIONS 
SERM, selective estrogen receptor modulators; HUVEC, human umbilical vein 
endothelial cells; mTOR, mechanistic target of rapamycin; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; S6K, ribosomal s6 kinase; ER, estrogen receptor; LDL, low-
density lipoprotein; NPC, Niemann-Pick Disease Type C; VEGFR2, vascular endothelial 
growth factor receptor 2; AIBP, apoA-I binding protein; PDGFRβ, platelet-derived 
growth factor receptor β; FGFR1, fibroblast growth factor receptor 1; LAMP1, lysosomal 
associated membrane protein 1; CD, cyclodextrin; TMX, tamoxifen; TRM, toremifene; 
CLM, clomifene; RLX, raloxifene; TUM, tunicamycin; ITRA, itraconazole.  
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4.2 Introduction 
          Tamoxifen and selective estrogen receptor modulators (SERM) have been used to 
treat hormone responsive, estrogen receptor (ER)-positive breast cancers since the 1980s. 
It has generally been accepted that the anticancer activity of tamoxifen is mainly 
attributable to its competitive antagonism to ER, thereby inhibiting the proliferation of 
ER-positive breast cancer cells (1). However, whether this is the only mechanism of 
action underlying the anticancer activity of SERM has been questioned since tamoxifen 
and other SERM also showed anticancer activity in ER-negative breast cancers (2-4). 
Since the 1990s, several groups have found that tamoxifen and SERM strongly inhibited 
angiogenesis by mechanisms independent of ER (5-7). Based on these findings, 
tamoxifen and other SERM are now being actively investigated as anti-angiogenic agents 
in clinical trials for cancer treatment (8-10). However, the underlying molecular 
mechanism by which tamoxifen inhibits angiogenesis has remained largely unknown.  
          Cholesterol is an essential component of cellular membranes and plays a key role 
in membrane permeability and fluidity. In addition to a structural role, it also functions in 
intracellular transport and cell signaling (11, 12). Serum cholesterol is delivered 
throughout the body in the form of low-density lipoprotein (LDL) and transported into 
cells through receptor-mediated endocytosis (13). Endocytosed LDL is transported to the 
late endosomes and lysosomes (endolysosomes) where cholesteryl esters are hydrolyzed 
and free cholesterol is released from the endosomal system for delivery to other 
compartments, including the plasma membrane and endoplasmic reticulum (14). One of 
the most important machineries of cholesterol trafficking in the endolysosomes is the 
Niemann-Pick type C (NPC) proteins (NPC1 and NPC2), which help acid lipasemediated 
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hydrolysis of cholesteryl esters and deliver free cholesterol out of the endolysosomes 
(15). Inhibition of NPC1 or 2 causes accumulation of cholesterol and glycolipids in the 
endolysosomes, a phenotype called NPC after the genetic disease of the same name 
(16). 
          We have previously reported that a newly identified antiangiogenic drug 
itraconazole inhibited cholesterol trafficking and induced NPC-like phenotype in 
endothelial cells (17). Inhibition of cholesterol trafficking by itraconazole is accompanied 
by inhibition of mTOR signaling and VEGFR2 glycosylation, both of which are essential 
signaling components for endothelial cell proliferation (17, 18). Recently, Fang et al. 
showed that upon over-expression, apoA-I binding protein (AIBP), which is responsible 
for cholesterol efflux from endothelial cells, inhibited angiogenesis by depleting 
cholesterol from the plasma membrane, thereby inhibiting the VEGFR2 signaling 
pathway in endothelial cells and animal models (19). Similar to AIBP over-expression, 
cells with NPC phenotype induced by small molecules showed accumulation of 
cholesterol in the endolysosomes leading to cholesterol depletion in plasma membrane 
and inhibition of the VEGFR2 signaling pathway (17, 18). These results strongly suggest 
that cholesterol trafficking in endothelial cells is critical for proper angiogenesis. 
          In the present study, we found that tamoxifen and other SERM inhibited 
cholesterol trafficking in endothelial cells. Blockade of cholesterol trafficking by SERM 
fled to an abnormal subcellular distribution of mTOR and VEGFR2 and caused inhibition 
of their signaling pathways in a cholesterol-dependent manner. These data suggest that 
tamoxifen and other SERM inhibit angiogenesis by interfering with cholesterol 
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4.3 Materials and methods 
Cells and reagents 
          Pooled human umbilical vein endothelial cells (HUVEC) were purchased from 
Lonza (Allendale, NJ) and were grown in endothelial cell growth medium-2 (EGM-2) 
using the EGM-2 bullet kit (Lonza). MCF-7 (ER-positive) breast cancer cellswere grown 
in Roswell Park Memorial Institute (RPMI)-1640 medium containing 10% fetal bovine 
serum (FBS, Life Technologies, Grand Island, NY) and 1% antibiotics (penicillin and 
streptomycin) solution (Life Technologies).MDA-MB-231 (triple negative) breast cancer 
cells were grown in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% FBS (Life Technologies) and 1% antibiotics. All the cells were maintained in a 
humidified incubator at 37 °C adjusted to 5% CO2. Methyl-β-cyclodextrin, cholesterol 
and filipin were purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human 
VEGF-165 was purchased from R&D Systems (Minneapolis, MN). 
 
Filipin staining 
          Filipin staining was performed as described with slight modifications [17]. 
HUVEC were cultured in a Nunc Lab-Tek II 8-Chamber Slide (Thermo Scientific, 
Rockford, IL) at 1 × 104 cells/well. Cells were treated with SERM with or without 
cholesterol and cyclodextrin complex for 24 h. Cells were then fixed with 4% 
paraformaldehyde for 20min at room temperature and stained with filipin at a final 
concentration of 50 µg/ml in the dark for 1 h at room temperature. Cells were washed 
with PBS, mounted with Immu-mount (Thermo Scientific), and observed under a Zeiss 
510 Meta multiphoton confocal microscope (Carl Zeiss, Thornwood, NY). 
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Immunofluorescence imaging 
          For co-staining of proteins and cholesterol, HUVEC (1 × 104 cells/well) grown in a 
Nunc Lab-Tek II 8-Chamber Slide were treated with compounds for 24 h, fixed with 4% 
paraformaldehyde for 20 min at room temperature and stained with filipin (50 µg/ml) for 
1 h at room temperature. Cells were then permeabilized with 0.2% saponin supplemented 
with 50 µg/ml filipin and 5% bovine serum albumin (BSA) in PBS for 30 min. Cells were 
incubated with primary antibodies in PBS together with 50 µg/ml filipin, 0.05% saponin 
and 5% BSA overnight at 4 °C. Cells were then incubated with secondary antibodies in 
PBS with 50 µg/ml filipin, 0.05% saponin and 5% BSA at room temperature for 1 h. 
Cells were washed with PBS, mounted with Immumount, and observed under a Zeiss 510 
Meta multiphoton confocal microscope. For general immunofluorescence, cells were 
fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.5% Triton X-100 for 
10min and washed with PBS prior to blocking in 1% BSA in PBS containing 0.1% 
Tween 20 (PBST) for 1 h. Cells were then incubated with primary antibodies including 
anti-VEGFR2 (Cell Signaling Technology, Danvers, MA), anti-LAMP1 (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti mTOR (Cell Signaling Technology) and anti-
GM130 (BD Biosciences, San Jose, CA) in the blocking solution overnight at 4 °C, and 
then incubated with secondary antibodies conjugated with Alexa-Fluo488 or Alexa-
Fluo594 for 1 h. The cellular nuclei were stained with 4’,6-diamidino-2-phenylindole 
(DAPI) and actin cytoskeleton was stained with rhodamine-phalloidin (Life 
Technologies). The immunofluorescence images were obtained using the Zeiss 510 Meta 
multiphoton confocal microscope. 
 
	   139	  
[3H]-thymidine DNA incorporation assay 
          HUVEC, MCF-7 or MDA-MB-231were seeded at 3 × 103 cells/well in 96-well 
plates and allowed to adhere at 37 °C for 24 h. Cells were then treated with compounds 
for 24 h prior to being pulsed with 0.5 µCi [3H]-thymidine (PerkinElmer, Waltham, MA) 
for 16 h and then trypsinized. The cells were harvested onto FilterMat A glass fiber filters 
(Wallac, Turku, Finland) using a Harvester 96 cell harvester (Tomtec, Hamden, CT), and 
the radioactivity of [3H]-thymidine incorporated into DNA was counted using a 
MicroBeta liquid scintillation plate reader (PerkinElmer). The IC50 values and 95% 
confidence intervals were calculated using the GraphPad Prism 5.0 software (GraphPad 
Software, San Diego, CA). 
 
AlamarBlue cell viability assay 
          HUVEC, MCF-7 or MDA-MB-231were seeded at 3 × 103 cells/well in 96-well 
plates and allowed to adhere at 37 °C for 24 h. The cells were treated with compounds in 
the presence or absence of cholesterol or cyclodextrin, or both for 24 h. AlamarBlue 
reagent (Life Technologies) was added to the media at a final concentration of 10% and 
the incubation was continued for an additional 2 h. The fluorescence signal was read with 
an excitation wavelength of 570 nm and an emission wavelength of 590 nm using a 
SpectraMax M5 fluorescence microplate reader (Molecular Devices, Sunnyvale, CA). 
 
Western blot analysis 
          HUVEC (2 × 105 cells/well) were seeded in 6-well plates and allowed to adhere 
overnight. Following drug treatment for 24 h, cells were lysed by adding 2× Laemmli 
	   140	  
buffer containing 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol 
blue, 0.125MTris–HCl, pH 6.8 and the lysateswere boiled for 10 min and vortexed. After 
SDS-PAGE, the proteins were transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, CA). The blots were blocked with 5% non-fat dried milk at room temperature 
for 1 h, incubated with the primary antibodies including anti-VEGFR2 (Cell Signaling 
Technology), anti-phospho-VEGFR2 (Tyr1175, Cell Signaling Technology), anti-FGFR1 
(Cell Signaling Technology), anti-mTOR (Cell Signaling Technology), anti-phospho 
mTOR (Ser2448, Cell Signaling Technology), anti-S6K (Cell Signaling Technology), 
anti-phospho-S6K (Thr389, Cell Signaling Technology), anti-PDGFRβ (Santa Cruz 
Biotechnologies), anti-actin (Santa Cruz Biotechnologies) or anti-α-tubulin (Santa Cruz 
Biotechnologies) antibodies overnight at 4 °C and then incubated with HRP-conjugated 
secondary antibodies at room temperature for 1 h. The immunecomplexes were detected 
using enhanced chemiluminescence (ECL) detection reagent (GE Healthcare, Pittsburgh, 
PA). 
 
Endothelial cell tube formation assay 
          A 96-well plate was coated with 50 µl Matrigel (BD Biosciences) and was 
incubated at 37 °C for 1 h to allow for polymerization. HUVEC were mixed with 
appropriate compounds and seeded (2 × 104 cells/well) on the Matrigel-coated wells, 
followed by incubation in a CO2 incubator for 16 h. Cells were washed carefully with 
PBS once and Calcein-AM (2 µM in PBS, Life Technologies) solution was added to the 
cells. After incubation at 37 °C for 30 minutes, the cells were washed gently with PBS 
and the fluorescence-labeled tubular structures were observed under a Nikon Eclipse 
	   141	  
TS100 fluorescence microscope with an excitation wavelength of 485 nm and an 
emission wavelength of 520 nm at magnification ×100. The total tube lengths, sizes and 
number of junctions from the fluorescence images were quantified using the AngioQuant 




          Statistical significance of the data between control and test groups was determined 
by two-sided Student’s t-test using the GraphPad Prism 5.0 software. The P values less 
than 0.05 were considered significant. 
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4.4 Results 
Tamoxifen and SERM induce NPC-like phenotype in HUVEC 
          We tested four FDA-approved SERM including tamoxifen, toremifene, clomifene 
and raloxifene (Figure 4.1) for effects on cholesterol trafficking in HUVEC. Intracellular 
cholesterol was visualized by staining fixed cells with filipin (20). All four SERM 
induced accumulation of cholesterol in the perinuclear region of HUVEC, a phenotype 
similar to NPC and that induced by itraconazole (Figure 4.2). The cell morphology was 
also changed from large flat morphology into a partially shrunken form. These effects, 
however, were reversed upon addition of exogenous cholesterol and its carrier methyl-β-
cyclodextrin (CD) (Figure 4.3), suggesting that they are mediated largely through 
inhibition of cholesterol trafficking. 
  
 




Figure 4.2: Effect of SERM on cholesterol trafficking in HUVEC.  
(a) HUVEC were treated with tamoxifen (TMX), toremifene (TRM), clomifene (CLM) 
and raloxifene (RLX) for 24 h, and intracellular cholesterol was visualized by filipin. (b) 
HUVEC were treated with itraconazole (ITRA) for indicated time points, and 
intracellular cholesterol was visualized by filipin. Representative confocal images from 
four independent experiments are shown. 
 
 
Figure 4.3: Rescue effect by addition of exogenous cholesterol.  
(a) HUVEC were treated with 1 μM tamoxifen (TMX, upper panel) or 1 μM toremifene 
(TRM, lower panel) in the presence or absence of cholesterol (5 μg/ml)/cyclodextrin 
(0.1%) complex (Chol/CD) for 24 h, and intracellular cholesterol was visualized by 
filipin. (b) HUVEC were treated with 1 mM itraconazole (ITRA) in the presence or 
absence of cholesterol (5 mg/ml)/cyclodextrin (0.1%) complex (Chol/CD) for 24 h, and 
intracellular cholesterol was visualized by filipin. Representative confocal images from 
four independent experiments are shown. 
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Tamoxifen traps VEGFR2 in Golgi and induces perinuclear positioning of 
lysosomes in HUVEC 
          We have previously reported that a cholesterol trafficking inhibitor, itraconazole, 
inhibited the VEGFR2 and mTOR signaling pathways, both of which have been shown to 
be critical for angiogenesis (17, 18). To determine the effect of tamoxifen on VEGFR2 
and mTOR signaling, we first analyzed the subcellular localization of those two proteins. 
Immunofluorescence labeling showed that VEGFR2 was localized largely in the plasma 
membrane and some in intracellular regions in control HUVEC (Figure 4.4 a). Treatment 
of cells with tamoxifen caused an accumulation of a significant amount of VEGFR2 in 
the perinuclear region, which colocalized with the Golgi marker GM130 (Figure 4.4 a 
and b). To determine if the abnormal subcellular distribution of VEGFR2 caused by 
tamoxifen is due to the inhibition of cholesterol trafficking, we added cholesterol/CD 
complex to the cell culture media. VEGFR2 mislocalization by tamoxifenwas clearly 
reversed by the cholesterol/CD complex (Figure 4.4 b). On the other hand, mTOR was 
mainly located in the peripheral cytoplasm in control HUVEC and was well co-localized 
with the endolysosomal marker, LAMP1 (Figure 4.4 c). Tamoxifen treatment caused 
cholesterol accumulation in the perinuclear region overlapping with the LAMP1-positive 
endolysosomes. Though tamoxifen did not alter mTOR association with LAMP1-positive 
endolysosomes, the localization of both mTOR and lysosomes was confined to the 
perinuclear region in the tamoxifen-treated HUVEC, whereas both proteins were more 
evenly distributed in the cytoplasm in control HUVEC. Staining of the actin cytoskeleton 
clearly showed that mTOR localization was confined to the perinuclear region by 
tamoxifen treatment (Figure 4.4 d). This effect was reversed by cholesterol/CD complex 
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(Figure 4.4 d). These results indicated that tamoxifen caused subcellular redistribution of 
VEGFR2 and mTOR in endothelial cells in a cholesterol-dependent manner. 
  
Figure 4.4: Effects of SERM and cholesterol on the subcellular localization of 
VEGFR2 and mTOR in HUVEC. 
(a) HUVEC were treated with or without 1 μM tamoxifen (TMX) for 24 h and 
subcellular localization of VEGFR2 was assessed under a confocal microscope. Arrows 
indicate VEGFR2. (b) HUVEC were treated with or without 1 μM tamoxifen (TMX) in 
the presence or absence of cholesterol (5 μg/ml)/cyclodextrin (0.1%) complex (Chol/CD) 
for 24 h and subcellular localization of VEGFR2 and Golgi (GM130) was assessed. (c)
HUVEC were treated with or without 1 μM tamoxifen (TMX) for 24 h and subcellular 
localization of cholesterol (Filipin), lysosomes (LAMP1), and mTOR was assessed. (d) 
HUVEC were treated with 1 μM tamoxifen (TMX) in the presence or absence of 
	   149	  
cholesterol (5 µg/ml)/cyclodextrin (0.1%) complex (Chol/CD) for 24 h and subcellular 
localization of mTOR and actin was assessed. Arrows indicate that tamoxifen induced a 
change in mTOR localization from peripheral cytoplasm to the perinuclear region and 
this was reversed by cholesterol–cyclodextrin complex. Representative confocal images 
from four independent experiments are shown. 
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Tamoxifen inhibits VEGFR2 glycosylation and mTOR activity in HUVEC 
          Proper subcellular localization of proteins is critical for their proper function. Like 
other cell surface proteins, VEGFR2 is highly glycosylated and is expressed on the cell 
surface upon completion of glycosylation. Protein glycosylation occurs co-translationally 
in the endoplasmic reticulum and subsequently in the Golgi by a series of glycosidases 
and glycosyltransferases located in each organelle (21). Abnormal subcellular 
localization of glycoproteins will cause improper glycosylation and, therefore, affect their 
functions. As tamoxifen caused abnormal subcellular distribution of VEGFR2, we 
determined the effect of tamoxifen on the glycosylation pattern and the activity of 
VEGFR2. Control HUVEC showed two glycosylated forms of VEGFR2 (200 and 230 
kD) (Figure 4.5 a). The 230 kD (mature terminal glycosylated form) protein band was 
dominant over the 200 kD (intermediate glycosylated form) band. Tunicamycin is a 
glycosyltransferase inhibitor that acts in an initial step of glycosylation in the 
endoplasmic reticulum. It completely inhibited VEGFR2 glycosylation, reducing the 
protein’s mass to 180 kD as expected. Deoxymannojirimycin (dMM), an inhibitor of 
α-mannosidases, and itraconazole are known to inhibit terminal glycosylation, thus 
shifting the VEGFR2 from 230 to 200 kD form. Similar to dMM and itraconazole, 
tamoxifen and other SERM caused a shift in the apparent molecular mass of VEGFR2 
from 230 to 200 kD, suggesting that they inhibited terminal glycosylation which mainly 
occurs in the Golgi. Inhibition of terminal glycosylation of VEGFR2 by SERM occurred 
in a concentration-dependent manner (Figure 4.5 b - d). 
          Subcellular localization of mTOR is also important for its activity. Recently, it was 
reported that nutrient starvation induced abnormal lysosomal positioning (increase in 
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perinuclear positioning) (22). This perinuclear lysosomal positioning was accompanied 
by mTOR Complex-1 (mTORC1) redistribution and inhibited the activity of mTOR. 
Tamoxifen and other SERM also caused perinuclear lysosomal positioning (Figure 4.4 c 
and d) and inhibited the phosphorylation of S6 kinase (S6K), a substrate of mTORC1, in 
HUVEC (Figure 4.5 b - d). To further validate the inhibitory effect of tamoxifen on 
mTORC1 activity, the phosphorylation status of mTOR at Ser2448 was assessed. Like 
the direct mTOR inhibitor rapamycin, tamoxifen dose-dependently inhibited mTOR 
phosphorylation at Ser2448 in HUVEC (Figure 4.6 a). The phosphorylation of S6K was 
also inhibited by tamoxifen in parallel with the inhibition of mTOR phosphorylation. 
          We next examined glycosylation patterns of other receptor tyrosine kinases related 
to angiogenesis, including fibroblast growth factor receptor 1 (FGFR1) and platelet-
derived growth factor receptor β (PDGFRβ), to see if the tamoxifen effect was specific to 
VEGFR2. Similar to the effect observed on VEGFR2, tamoxifen caused a shift in the 
apparent molecular mass of PDGFRβ and FGFR1 (Figure 4.6 b). Sorafenib, a kinase 
inhibitor, had no effect on the receptor molecular masses. However dMM caused a shift 
in the receptors’ molecular masses in a manner similar to that of tamoxifen, suggesting 
that tamoxifen inhibited terminal glycosylation of the receptor tyrosine kinases. These 
results suggested that tamoxifen inhibits a common pathway in terminal glycosylation of 
receptor tyrosine kinases in endothelial cells. 
  
Figure 4.5: Effect of SERM on VEGFR2 glycosylation and mTORC1 pathway in 
HUVEC.  
(a) HUVEC were treated with SERM including tamoxifen (TMX, 5 μM), toremifene 
(TRM, 5 μM) and clomifene (CLM, 5 μM) for 24 h and VEGFR2 glycosylation was 
assessed byWestern blotting. Glycosylation inhibitors including deoxymannojirimycin 
(dMM, 500 μM) and tunicamycin (TUM, 2 μg/ml), and a cholesterol trafficking inhibitor 
itraconazole (ITRA, 1 μM) were used as positive controls. Three different glycosylated 
forms of VEGFR2 (a: 230 kD hyper-glycosylated form, b: 200 kD intermediate 
glycosylated form and c: 180 kD unglycosylated form) are shown. (b - d) Effect of 
various concentrations of SERM on VEGFR2 glycosylation and mTORC1 pathway – 
indicated by the level of phosphorylated S6K (pS6K) – are shown. Representative 
Western blot images from three independent experiments are shown. 
Figure 4.6: Effect of tamoxifen on the phosphorylation of mTOR and the 
glycosylation of receptor tyrosine kinases in HUVEC. 
(a) HUVEC were treated with tamoxifen (TMX) or rapamycin (Rapa) at indicated 
concentrations for 24 h and the phosphorylation of mTOR at Ser2448 as well as 
phosphorylated S6K (pS6K) and total S6K was analyzed. (b) HUVEC were treated with 
tamoxifen (TMX), sorafenib (Soraf) or deoxymannojirimycin (dMM) at indicated 
concentrations for 24 h. The terminal glycosylation of the receptor tyrosine kinases was 
assessed by Western blotting using specific antibodies against each receptor tyrosine 
kinase in the presence of the known glycosylation inhibitor dMM. Representative 
Western blot images from three independent experiments are shown. 
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Cholesterol reverses the inhibitory effects of tamoxifen on VEGFR2 and mTOR 
signaling in HUVEC 
          We next determined the effect of cholesterol on the inhibition of VEGFR2 
glycosylation by tamoxifen in HUVEC. Inhibition of terminal glycosylation by either 
tamoxifen or toremifene was completely reversed by the addition of cholesterol/CD 
complex (Figure 4.7 a and b). To see if the inhibition of terminal glycosylation by 
tamoxifen affected VEGFR2 activity/signaling, tyrosine phosphorylation status of 
VEGFR2 was assessed. Inhibition of terminal glycosylation of VEGFR2 by tamoxifen 
led to the inhibition of VEGFR2 phosphorylation, which was completely reversed by 
cholesterol/CD complex (Figure 4.7 c). A VEGFR2 tyrosine kinase inhibitor sunitinib 
also inhibited VEGFR2 phosphorylation. But this effect was not reversed by 
cholesterol/CD complex (Figure 4.7 c). These data suggested that the effect of tamoxifen 
on VEGFR2 was mediated through inhibition of cholesterol trafficking in endothelial 
cells. We further investigated the effect of cholesterol on inhibition of mTOR signaling 
by tamoxifen in HUVEC. Inhibition of S6K phosphorylation by either tamoxifen or 
toremifene was completely reversed by cholesterol/CD complex (Figure 4.7 d). CD 
alone could partially reverse tamoxifen activity. This was presumably due to the reversal 
effect of CD on NPC phenotype by releasing free cholesterol from endolysosomes (23). 
Inhibition of mTOR signaling by tamoxifen and its reversal by cholesterol were further 
confirmed by examining 4E-BP1 phosphorylation, which was also decreased (Figure 
4.8). 
 
Figure 4.7: Reversal effect of cholesterol on the inhibition of VEGFR2 and mTOR 
activities by SERM.  
(a and b) HUVEC were treated with tamoxifen (TMX) or toremifene (TRM) with or 
without cholesterol (5 μg/ml)/cyclodextrin (0.1%) complex (Chol/CD) for 24 h, and 
VEGFR2 glycosylation was assessed by Western blotting. (c) HUVEC were grown in 
low serum media (0.1% FBS without additional growth factor supplements) and treated 
with drugs including tamoxifen (TMX) and sunitinib (Sunit, 100 nM) for 24 h in the 
presence or absence of cholesterol (5 μg/ml)/cyclodextrin (0.1%) complex (Chol/CD). 
Cells were then stimulated with 50 ng/ml of VEGF-165 for 5 min and the levels of total 
and phosphorylated VEGFR2 were assessed by Western blotting. (d) HUVEC were 
treated with tamoxifen (TMX, 5 μM) or toremifene (TRM, 5 μM) with or without 
cholesterol (Chol, 5 μg/ml) and cyclodextrin (CD, 0.1%) for 24 h, and mTOR activity 
was assessed by Western blotting of phosphorylated S6-kinase (pS6K). Representative 
Western blot images from three independent experiments are shown. 
Figure 4.8: Reversal effect of cholesterol on inhibition of mTOR activity by SERM.  
HUVEC were treated with tamoxifen (TMX), toremifene (TRM) or clomifene (CLM) 
with or without cholesterol (Chol, 5 mg/ml)/cyclodextrin (CD, 0.1%) complex (Chol/CD) 
for 24 h, and mTOR activity was assessed by Western blotting of 4E-BP1. 4E-BP1 has 
multiple protein bands and lower molecular weight bands represent hypophosphorylated 
4E-BP1. Note that SERM decreased the phosphorylation of 4E-BP1 as shown by 
decrease in the levels of higher molecular weight forms of 4E-BP1. Representative 
Western blot images from three independent experiments are shown. 
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Cholesterol reverses the inhibitory effects of tamoxifen on HUVEC proliferation 
          To assess the relationship between VEGFR2 phosphorylation, mTOR activity and 
cell proliferation, we examined the effect of SERM on HUVEC proliferation. Half 
maximal inhibitory concentrations (IC50) of tamoxifen, toremifene and raloxifene for 
HUVEC proliferationwere determined to be 0.98, 1.2, and 1.42 µM, respectively (Figure 
4.9 a and Table 4.2).We then determined if cholesterol could reverse the inhibition of 
HUVEC proliferation by SERM. Tamoxifen and toremifene strongly inhibited the growth 
of HUVEC at 2 and 4 µM, respectively. The inhibitions were partially reversed by CD 
and were fully reversed by cholesterol/CD complex (Figure 4.9 b). Cholesterol alone has 
no reversal effect on the cell growth inhibition by tamoxifen or toremifene. These data 
corroborated the effects of SERM on VEGFR2 and mTOR (Figure 4.7 a - d). 
  
Figure 4.9: Effects of SERM and cholesterol on HUVEC proliferation.  
(a) HUVEC were treated with various concentrations of tamoxifen, toremifene or 
raloxifene for 24 h and cell proliferation was assessed through the [3]H-thymidine uptake 
assay. (b) HUVEC were treated with tamoxifen (TMX, 2 μM) or toremifene (TRM, 4 
μM) for 24 h and were observed under a phase contrast microscope. Cholesterol (Chol, 5 
μg/ml) and cyclodextrin (CD, 0.1%) were added together to assess reversibility on the 
anti-proliferative effect of SERM. NT denotes not treated with Chol/CD. Representative 
phase-contrast images from four independent experiments are shown. The cell viability 
was quantified by AlamarBlue staining and was plotted using the GraphPad Prism 5.0 
software (right panel). Data represent mean ± standard deviation (SD) from four 
independent experiments. **P < 0.01 between two indicated groups. 
  
	   159	  
Table 4.2. Half-maximum inhibitory concentrations (IC50) of SERM on cell 
proliferation and 95% confidence intervals (CI) are shown. 
Drugs 
HUVEC MCF-7 (ER+) MDA-MB-231 (ER-) 
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Inhibition of cholesterol trafficking by tamoxifen is independent of ER 
          SERM are potent antagonists of ER, with Kd values ranging from picomolar to 
single-digit nanomolar concentrations, hence showing anti-proliferative effects on ER-
positive breast cancer cells (24). We thus tested whether SERM have different sensitivity 
on cell proliferation and cholesterol trafficking in cells with different ER expression 
statuses. In an ER-positive cell line (MCF-7), SERM showed a biphasic cell growth 
inhibition; marginal inhibition at lower concentrations (from nanomolar to single-digit 
micromolar, dotted arrows) and strong/complete inhibition at higher concentrations (from 
single- to double-digit micromolar, solid arrows) (Figure 4.10 a). In an ER-negative cell 
line (MDA-MB-231), SERM showed a typical dose–response curve with growth 
inhibition at higher concentrations (from single- to double-digit micromolar) (Figure 
4.10 b). These data suggested that SERM have at least two independent targets for 
growth inhibition in MCF-7 cells. It could be postulated that the more sensitive target is 
ER while the less sensitive target is cholesterol trafficking in ER-positive MCF-7 cells.  
          We further tested the effect of a high concentration of tamoxifen (10 µM) on 
cholesterol trafficking in both MCF-7 and MDA-MB-231. Tamoxifen strongly inhibited 
cholesterol trafficking in both cells and the inhibition was reversed by cholesterol/CD 
complex (Figure 4.11 a). A high concentration of tamoxifen strongly inhibited the cell 
growth of both MCF-7 and MDA-MB-231 and the inhibition was reversed by 
cholesterol/CD complex (Figure 4.11 b). These data demonstrated that inhibition of 
cholesterol trafficking by tamoxifen is independent of its action on ER. 
  
Figure 4.10: Effects of SERM and cholesterol on ER-positive or ER-negative breast 
cancer cell proliferation.  
(a) MCF-7 (ER-positive) or (b) MDA-MB-231 (ER-negative) cells were treated with 
various concentrations of tamoxifen, toremifene or raloxifene for 24 h and cell 
proliferation was assessed through the [3]H-thymidine uptake assay. SERM showed a 
biphasic growth inhibition in MCF-7 cells. Dotted arrows indicate concentration ranges 
that show marginal cell growth inhibition, whereas solid arrows represent concentration 
ranges with strong cell growth inhibition. The cell viability was quantified by 
AlamarBlue staining and was plotted using the GraphPad Prism 5.0 software. Data 
represent mean ± standard deviation (SD) from four independent experiments. 
  
Figure 4.11: Tamoxifen strongly inhibited cholesterol trafficking in both cells and 
the inhibition was reversed by cholesterol/CD complex.  
(a) MCF-7 or MDA-MB-231 cells were treated with 10 μM tamoxifen (TMX) in the 
presence or absence of cholesterol (5 μg/ml)/cyclodextrin (0.1%) complex (Chol/CD) for 
24 h and intracellular cholesterol was labeled with filipin staining. Representative 
confocal images from four independent experiments are shown. (b) MCF-7 or MDA-
MB-231 cells were treated with 10 μM tamoxifen (TMX) in the presence or absence of 
cholesterol (Chol, 5 μg/ml)/cyclodextrin (CD, 0.1%) complex (Chol/CD) for 24 h. The 
cell viability was quantified by AlamarBlue staining and was plotted using the GraphPad 
Prism 5.0 software. Data represent mean ± standard deviation (SD) from four 
independent experiments. **P < 0.01 between two indicated groups. 
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Cholesterol reverses the inhibitory effect of tamoxifen on HUVEC tube formation in 
Matrigel 
          We determined the effect of SERM on endothelial cell tube formation, a well-
established in vitro assessment of angiogenesis. As expected from previous reports (5, 7), 
both tamoxifen and toremifene inhibited the tube formation of HUVEC on Matrigel 
(Figure 4.12 a). The inhibition of tube formation by SERM, however, was significantly 
reversed by an addition of cholesterol/CD complex, while cholesterol/CD itself did not 
affect the tube structures (Figure 4.12 a and b). Taken together, these results suggested 
that anti-angiogenic activity of tamoxifen is mainly mediated by its effect on cholesterol 
trafficking in endothelial cells.  
  
Figure 4.12: Effects of SERM and cholesterol on HUVEC tube formation.  
(a) HUVEC were seeded onto a Matrigel-coated plate to promote tube formation. Cells 
were treated with 5 μM tamoxifen (TMX) or 5 μM toremifene (TRM) in the presence or 
absence (NT) of cholesterol (5 μg/ml)/cyclodextrin (0.1%) complex (Chol/CD) for 18 h. 
The tube formation was visualized by staining with Calcein-AM under a fluorescence 
microscope. Representative fluorescence images from six independent experiments are 
shown. (b) Total tube lengths, sizes and number of junctions from the fluorescence 
images from six experiments were quantified using the AngioQuant software. **P < 0.01 
between two indicated groups.   
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4.5 Discussion 
          SERM are mixed agonists/antagonists of ER, which act differently depending on 
cell and tissue types. As they act as antagonists of ER in breast tissue, SERM, especially 
tamoxifen, have long been used to treat ER-positive breast cancer. However, it has been 
questioned whether the anticancer effect of SERM is solely due to the ER antagonism, 
since a number of reports have shown the therapeutic effects of tamoxifen on ER-
negative breast cancer (2-4). The anti-angiogenic activity of SERM was first reported by 
Gagliardi and Collins in 1993 (7). SERM including clomiphene and tamoxifen 
significantly inhibited angiogenesis in the chorioallantoic membrane in growing chick 
embryos. Addition of excessive amount of 17β-estradiol did not alter the anti-angiogenic 
activity of SERM, suggesting that angiogenesis inhibition by SERM was independent of 
the blockade of ER. Subsequent studies have demonstrated that SERM are effective anti-
angiogenic agents using several animal models, including ER-negative rat models (5, 6). 
Based on these observations, SERM are under review in several clinical studies as an 
antiangiogenic monotherapy or an adjuvant therapy with chemotherapy drugs in a broad 
range of cancer types (8-10). All the evidence strongly suggests that inhibition of 
angiogenesis is one of the major mechanisms underlying the anticancer activity of SERM 
in addition to ER. However, the mechanism underlying the anti-angiogenic activity of 
SERM has remained elusive. 
          In the present study, we showed that SERM inhibited cholesterol trafficking in 
endothelial cells, as evidenced by abnormal accumulation of free cholesterol in the 
endolysosomes. This effect was accompanied by aberrant subcellular localization of two 
major players in angiogenesis, VEGFR2 and mTOR, in endothelial cells. VEGFR2 
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undergoes glycosylation upon translation and the glycosylation is required for receptor 
auto-phosphorylation and activation (25). Tamoxifen treatment caused trapping of the 
VEGFR2 in the Golgi, inhibited the terminal glycosylation and depleted the receptor in 
the plasma membrane. Consequently, tamoxifen inhibited the VEGF-induced 
phosphorylation of VEGFR2 in endothelial cells. Tamoxifen also inhibited terminal 
glycosylation of other receptor tyrosine kinases related to angiogenesis such as FGFR1 
and PDGFRβ in HUVEC. These data suggest that tamoxifen inhibits a common terminal 
glycosylation pathway in endothelial cells leading to the inhibition of maturation of the 
receptor tyrosine kinases. On the other hand, mTORC1 is recruited to the lysosome 
surface and regulates lysosomal functions when cells are in normal nutrient-rich state 
(26). Conversely, mTOR activity is also regulated by lysosomes by altering subcellular 
lysosomal positioning (22). The lysosomal positioning is critical for mTOR activity (22, 
27, 28). Under starvation, intracellular pH (pHi) was increased and this pHi change in 
turn caused perinuclear clustering of lysosomes. The perinuclear clustering of lysosomes 
led to an inhibition of mTOR activity. Forced movement of lysosomes to the cell 
periphery by overexpressing kinesin family of proteins could restore mTOR activity, 
suggesting a critical role of lysosomal positioning in mTOR signaling pathway(22). In 
our study, we found that tamoxifen did not alter the association of mTOR with the 
LAMP1-positive endolysosomes. Instead, it switched lysosomal positioning from the cell 
periphery to the perinuclear region leading to the inhibition of mTOR activity. Although 
the mechanism by which lysosomal positioning influences mTOR activity remains to be 
elucidated, it has been proposed that lysosomes in the cell periphery would enable mTOR 
to access to its upstream signaling molecules such as activated Akt at the cell surface 
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membrane. Confining lysosomes to the perinuclear region would prevent mTOR from 
accessing its upstream signaling molecules at the cell membrane, leading to the blockade 
of its activation (22). Further studies are necessary to elucidate the causal relationship 
between SERM-induced lysosomal positioning and mTOR activity.  
          We further showed that addition of extracellular cholesterol could significantly 
reverse the abnormal localization of VEGFR2 and inhibition of terminal glycosylation 
and receptor phosphorylation caused by SERM. Cholesterol also could reverse SERM-
induced perinuclear lysosomal positioning and inhibition of mTOR activity. These data 
strongly suggest that cholesterol trafficking lies upstream of VEGFR2 trafficking and 
glycosylation and lysosomal positioning by SERM. In addition, inhibition of endothelial 
cell proliferation and tube formation by SERM was markedly reversed by the addition of 
extracellular cholesterol, implying that inhibition of cholesterol trafficking led to the 
inhibition of twomajor signaling pathways, VEGFR2 and mTOR, which is likely the 
main mechanism mediating the antiangiogenic activity of SERM.  
          In this study,we have not identified the molecular target responsible for the 
inhibition of endothelial cell cholesterol trafficking by SERM. ER could be a candidate, 
but it was ruled out by testing two different breast cancer cell lines, MCF-7 (ER-positive) 
and MDA-MB-231 (ER-negative). SERM at high concentrations caused abnormal 
cholesterol accumulation in both cell lines regardless of the ER status and inhibited cell 
proliferation in a cholesterol-dependent manner. One possible mechanism of cholesterol 
trafficking inhibition by SERM could be that SERM, especially tamoxifen, act as a 
lipophilic weak base and increase the pH in acidic organelles such as lysosomes (28). 
Changes in organellar pH could inhibit enzyme activities in the organelles including NPC 
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proteins and glycosylation enzymes, which could potentially affect cholesterol and 
receptor tyrosine kinase trafficking in the cells. Ongoing studies are focused on 
lysosomal pH change in endothelial cells and the results will be presented in the near 
future.  
          The vascular endothelium is the first layer of cells that are in contact with the full 
circulating lipoproteins from blood plasma, and is responsible for the uptake of LDL-
cholesterol from the plasma and efflux of cellular cholesterol to HDL in the plasma. 
Several recent reports showed that cholesterol uptake and efflux in endothelial cells are 
important regulators of angiogenesis (19, 29, 30). Usui et al. showed that LDL alone 
could activate VEGFR1 signaling in the absence of VEGF in macrophages (30). The 
activation of VEGFR1 signaling was mediated by recruitment of the LDL receptor to 
VEGFR1 by LDL during its uptake. Conversely, Fang et al. demonstrated that AIBP 
mediates cholesterol efflux from endothelial cells, and its overexpression suppresses 
angiogenesis in animal models through inhibition of VEGFR2 signaling (19). In our 
previous studies, itraconazole was found to inhibit cholesterol trafficking in endothelial 
cells (17). Itraconazole is undergoing multiple clinical studies as an anti-angiogenic 
agent. Several positive clinical results have been reported recently from Phase II studies 
for cancer treatment, including metastatic and castration-resistant prostate cancer, non-
small cell lung cancer and basal cell carcinoma (31-33). These studies together with our 
current results suggest that endothelial cell cholesterol trafficking can serve as a novel 
therapeutic target for angiogenesis-related diseases including cancer.   
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TECHNICAL SKILLS 
 
• Data analysis: data statistical analysis and display using R and GraphPad Prism. 
• Molecular Biology: PCR; plasmid construction (conventional, Infusion and 
Gateway); site-directed mutagenesis; DNA/RNA purification; quantitative RT-PCR; 
DNA electrophoresis 
• Biochemistry: expression of recombinant proteins in bacteria and mammalian cells; 
affinity purification; affinity and size-exclusion chromatography; 
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immunoprecipitation; tandem affinity pull-down; biotin pull-down; differential 
centrifugation; SDS-PAGE; immunoblotting; Coomassie blue staining; silver 
staining; in vitro kinase assay 
• Cell Biology: bacteria and mammalian cell culture; human primary cell culture; 
electroporation; plasmid transfection; production and harvest of lentivirus; lentiviral 
transduction; gene silencing (siRNA and shRNA); generation of stable cell lines; soft 
agar colony formation assay; 3D spheroid invasion assay; endothelial tube formation 
assay on Matrigel; cell cycle analysis using flow cytometry; immunofluorescent 
staining; sorting and identification of breast cancer stem cells 
• Microscopy: confocal microscopy 
• Pharmaceutics: preparation of lysosomes using a film dispersion method; 
characterization of the liposomes (encapsulation efficiencies, particle sizes, in vitro 
release, stability) 
• High-throughput Assays: determination of IC50, EC50, kcat, Km and Ki values; cell 
proliferation and viability assays ([3H]-thymidine incorporation, alamarBlue and 
Calcein AM assays) 
• Animal experiments: in vivo Matrigel plug angiogenesis assay; in vivo tumor 
xenograft assay; mouse gavage; mice intraperitoneal injection 
• Population PK/PD modeling: population PK/PD data analysis and modeling using 
NONMEM. 
• Other experimental skills: HPLC, structure–activity relationship studies  
• Computer Softwares:  R, NONMEM, Pirana, GraphPad Prism; ImageJ; CLC 
Sequence Viewer; Microsoft Office (Word, Excel & PowerPoint); Adobe Illustrator 
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OTHER ACADEMIC ACTIVITIES 
• Poster presentations: 06/2016 Gordon Research Seminar and Gordon Research 
Conferences (Phosphorylation & G-Protein Mediated Signaling Networks); 
• Discussion leader: Gordon Research Seminar 2016 (Phosphorylation & G-Protein 
Mediated Signaling Networks) 
HONORS AND AWARDS 
• Spring 2016  Scheinberg Travel Award, Johns Hopkins University 
• 2009 – 2010  National Scholarship for Outstanding Graduate Students in 
Pharmaceutical Sciences 
• 2007 – 2008  The Third Prize of Peking University Scholarship for Outstanding 
Biomedical Students 
• 2006 – 2007  The Second Prize of Peking University Scholarship for Outstanding 
Biomedical Students 
• 2005 – 2006  The Third Prize of Peking University Scholarship for Outstanding 
Biomedical Students 
ADDITIONAL INFO 
Language: English (fluent); Mandarin Chinese (native) 
 
